

FORM PTO-1390
(REV. 9-2001)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER

1406/37

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/030605

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/EP00/06698

13 July 2000 (13.07.00)

13 July 1999 (13.07.99)

TITLE OF INVENTION

DESIGN OF BETA-PLEATED SHEET PROTEINS WITH SPECIFIC BINDING PROPERTIES

APPLICANT(S) FOR DO/EO/US SCIL PROTEINS GMBH; FIEDLER, Ulrike and RUDOLPH, Rainer

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:

Copy of WO 01/04144; copy of English translation of Amended Claims; paper copy of English translation of sequence listing; copy of PCT/IPEA/409; copy of PCT/IPEA/402; copy of International Search Report

U.S. APPLICATION NO. 10/030605 INTERNATIONAL APPLICATION NO.

PCT/EP00/06698

ATTORNEY'S DOCKET NUMBER

1406/37

21. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):					
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.				\$1040.00	
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.				\$890.00	
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.				\$740.00	
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)				\$710.00	
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)				\$100.00	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$	890.00
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	0.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	25 - 20 =	5	x \$18.00	\$	90.00
Independent claims	1 - 3 =	0	x \$84.00	\$	0.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00	\$	0.00
TOTAL OF ABOVE CALCULATIONS =				\$	980.00
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	490.00
SUBTOTAL =				\$	490.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	0.00
TOTAL NATIONAL FEE =				\$	490.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	0.00
TOTAL FEES ENCLOSED =				\$	490.00
				Amount to be refunded:	\$
				charged:	\$

- a. ☒ A check in the amount of \$ 490.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0426. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Richard E. Jenkins
JENKINS & WILSON, P.A.
Suite 1400 University Tower
3100 Tower Boulevard
Durham, NC 27707
US



25297

PATENT TRADEMARK OFFICE

Richard E. Jenkins
SIGNATURE

Richard E. Jenkins
NAME

28,428
REGISTRATION NUMBER

"Express Mail" mailing number EV023031173US

Date of Deposit 9 Jan. 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, PO Box 2327, Arlington, VA 22202
Shay E. Dunn

531 Rec'd PCT/F

10/030605
09 JAN 2002

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Fiedler et al.

Group Art Unit: Not Assigned

Serial No.: Not Assigned

Examiner: Not Assigned

Filed: Herewith

Docket No.: 1406/37

For: DESIGN OF BETA-SHEET PROTEINS WITH SPECIFIC BINDING PROPERTIES

PRELIMINARY AMENDMENT

Honorable Commissioner for Patents
BOX PCT
Washington, D.C. 20231

Dear Sir:

Kindly amend the subject application as follows:

IN THE SPECIFICATION:

Please insert the paragraph heading on page 1 of the English translation of the subject application, before the title, as follows:

--Description--.

Please insert the paragraph heading on page 1 of the English translation of the subject application, before the first full paragraph, as follows:

--Technical Field--.

Please insert the paragraph heading on page 1 of the English translation of the subject application, before the second full paragraph, as follows:

--Background Art--.

Please insert the paragraph heading on page 2 of the English translation of the subject application, before the first full paragraph, as follows:

--Summary of the Invention--.

Please insert the paragraph heading on page 14 of the English translation of the subject application, before the fourth full paragraph, as follows:

--Brief Description of the Drawings--.

Please insert the paragraph heading on page 16 of the English translation of the subject application, before the sixth full paragraph, as follows:

--Detailed Description of the Invention--.

IN THE CLAIMS:

Please delete the paragraph heading on page 1 of the English translation of the Amended Claims, line 1, and insert in place thereof the paragraph heading as follows:

--CLAIMS--

Please insert the paragraph heading on page 1 of the English translation of the Amended Claims, before claim 1, the following:

– What is claimed is: –.

Please amend claims 1-17 and 19-25 as follows:

1. (Amended) Protein with beta-sheet structure, wherein amino acids exposed on the surface in at least two β -strands exposed on the surface of at least one beta sheet exposed on the surface are specifically substituted, deleted or inserted, such that the protein has new specific antigen binding properties or a new catalytic activity or new fluorescence properties.
2. (Amended) Protein according to Claim 1, wherein it is included in the group consisting of crystallines, spherulines, heat shock proteins, cold shock proteins, β -helix proteins, lipocalins, serpins, fibronectins or transcription factors or is GFP, NGF, tendamistat or lysozyme.
3. (Amended) Protein according to Claim 1, wherein, amino acids exposed on the surface in three beta strands exposed on the surface are substituted, deleted or inserted.
4. (Amended) Protein according to Claim 1, wherein, amino acids exposed on the surface in four or more beta strands exposed on the surface are substituted, deleted or inserted.
5. (Amended) Protein according to claim 1, wherein amino acids exposed on the surface in at least two beta strands in at least two beta sheets are substituted, deleted or inserted.
6. (Amended) Protein according to claim 1, wherein, amino acids exposed on the surface in three beta strands in two antiparallel beta sheets are substituted, deleted or inserted.
7. (Amended) Protein according to claim 1, wherein it is a crystalline of vertebrates, preferably rodents, birds or fish.
8. (Amended) Protein according to claim 1, wherein, it is an alpha-, beta- or gamma-crystalline.
9. (Amended) Protein according to claim 1, wherein, it is a gamma-II-crystalline protein.
10. (Amended) Protein according to claim 1, wherein amino acids exposed on the surface of the protein are substituted, deleted or inserted in a region of the beta sheet accessible to a solvent or to a binding partner.
11. (Amended) Protein according to claim 1, wherein, amino acids exposed on the surface are substituted, deleted or inserted in a β -sheet structure of a domain or a subunit of the protein.
12. (Amended) Protein according to claim 1, wherein, it is a gamma-II-crystalline which has been obtained by substitution, deletion or insertion of one or

more of the amino acids Lys 2, Thr 4, Tyr 6, Cys 15, Glu 17, Ser 19, Arg 36 and Asp 38 in gamma-II-crystalline.

13. (Amended) Protein according to claim 1, wherein, amino acids exposed on the surface of the protein have been substituted, deleted or inserted in the beta sheet such that it has antibody-like binding properties or an enzymic (catalytic) activity.

14. (Amended) Protein according to Claim 12, wherein it has binding specificity for estradiol or the conjugate thereof, BSA- β -estradiol-17-hemisuccinate.

15. (Amended) Protein according to claim 1, wherein, it has binding specificity for estradiol or the conjugate thereof, BSA- β -estradiol-17-hemisuccinate and has the amino acid sequence SEQ ID NO. 19 or SEQ ID NO. 21.

16. (Amended) Protein according to claim 1, wherein, it is combined with other proteins or non-protein substances.

17. (Amended) DNA coding for a protein according to claim 1.

19. (Amended) Prokaryotic or eukaryotic vectors or cells comprising a DNA or RNA according to Claim 17 or parts thereof coding for functional regions of the protein.

20. (Amended) Method for preparing a protein according to claim 1, comprising the following steps:

a. Mutagenesis of the DNA coding for a protein with beta-sheet structure in those regions which code for at least two beta strands, exposed on the surface, of a beta sheet exposed on the surface;

b. Expression of the mutants obtained in step (a) in a suitable expression system; and

c. Selection and isolation of mutants having the desired binding properties and/or the desired catalytic activity; optionally

d. Expression and purification of the beta sheet-mutated proteins.

21. (Amended) Method according to Claim 20, wherein the mutagenesis comprises a substitution, deletion or insertion of specific amino acid positions (site-specific mutagenesis) or non-specific amino acid positions (random mutagenesis) in the beta sheet.

22. (Amended) Method according to claim 20, wherein, the mutants in step b) are expressed in prokaryotic or eukaryotic cells, in a cell-free system as a complex with ribosomes or on the surface of plant or animal cells, yeast cells or phages, viruses or bacteria.

23. (Amended) Method according to claim 20, wherein mutants having the desired binding properties are selected by contacting these mutants with the binding partner and isolating those mutants having the desired binding affinity.

24. (Amended) Method according to claim 20, wherein mutants having the desired catalytic properties are selected by contacting these mutants with their substrate and isolating those mutants having the desired catalytic activity.

25. (Amended) Use of a protein according to claim 1, in diagnostics and therapy, in cosmetics, bioseparation and biosensors and reduction of harmful substances.

REMARKS

The amendments to the specification as set forth above are intended to clarify and set apart the various sections of the subject application.

The amendments to the claims as set forth above are intended to remove all multiple dependent claims from the subject application and to more particularly point out and distinctly claim the subject invention.

Attached hereto is a marked-up version of the specification and claims 1-17 and 19-25, which illustrates all of the changes made to the specification and claims pursuant to 37 CFR §1.121. The attached page is captioned "Version With Markings To Show Changes Made". Deleted language is bracketed and added language is underlined.

The Commissioner is hereby authorized to charge any deficiencies or credit any overpayments in connection with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.

Date: 1-9-02

By:

Richard E. Jenkins
Richard E. Jenkins
Reg. No.: 28,428

Suite 1400 University Tower
3100 Tower Boulevard
Durham, North Carolina 27707
Telephone: (919) 493-8000
Facsimile: (919) 419-0383



1406/37

REJ/lsg

Serial No.: Not yet assigned

Version With Markings To Show Changes Made

IN THE SPECIFICATION:

The paragraph heading has been inserted on page 1 of the English translation of the subject application, before the title, as follows:

Description

The paragraph heading has been inserted on page 1 of the English translation of the subject application, before the first full paragraph, as follows:

Technical Field

The paragraph heading has been inserted on page 1 of the English translation of the subject application, before the second full paragraph, as follows:

Background Art

The paragraph heading has been inserted on page 2 of the English translation of the subject application, before the first full paragraph, as follows:

Summary of the Invention

The paragraph heading has been inserted on page 14 of the English translation of the subject application, before the fourth full paragraph, as follows:

Brief Description of the Drawings

The paragraph heading has been inserted on page 16 of the English translation of the subject application, before the sixth full paragraph, as follows:

Detailed Description of the Invention

IN THE CLAIMS:

The paragraph heading "Patent Claims" on page 1 of the English translation of the Amended Claims has been deleted and the paragraph heading has been inserted in place thereof as follows:

CLAIMS

The paragraph heading has been inserted on page 1 of the English translation of the Amended Claims, before claim 1, as follows:

What is claimed is:

1. (Amended) Protein with beta-sheet structure, [characterized in that] wherein amino acids exposed on the surface in at least two β -strands exposed on the surface of at least one beta sheet exposed on the surface are specifically substituted, deleted or inserted, such that the protein has new specific antigen binding properties or a new catalytic activity or new fluorescence properties.

2. (Amended) Protein according to Claim 1, [characterized in that] wherein it is included in the group consisting of crystallines, spherulines, heat shock proteins, cold shock proteins, β -helix proteins, lipocalins, serpins, fibronectins or transcription factors or is GFP, NGF, tendamistat or lysozyme.

3. (Amended) Protein according to Claim 1 [or 2, characterized in that], wherein, amino acids exposed on the surface in three beta strands exposed on the surface are substituted, deleted or inserted.

4. (Amended) Protein according to Claim 1 [or 2, characterized in that], wherein, amino acids exposed on the surface in four or more beta strands exposed on the surface are substituted, deleted or inserted.

5. (Amended) Protein according [one or more of the preceding claims, characterized in that] to claim 1, wherein amino acids exposed on the surface in at least two beta strands in at least two beta sheets are substituted, deleted or inserted.

6. (Amended) Protein according to [one or more of the preceding claims, characterized in that] claim 1, wherein, amino acids exposed on the surface in three beta strands in two antiparallel beta sheets are substituted, deleted or inserted.

7. (Amended) Protein according to [one or more of the preceding claims, characterized in that] claim 1, wherein it is a crystalline of vertebrates, preferably rodents, birds or fish.

8. (Amended) Protein according to [one or more of the preceding claims, characterized in that] claim 1, wherein, it is an alpha-, beta- or gamma-crystalline.

9. (Amended) Protein according to [one or more of the preceding claims, characterized in that] claim 1, wherein, it is a gamma-II-crystalline protein.

10. (Amended) Protein according to [one or more of the preceding claims, characterized in that] claim 1, wherein amino acids exposed on the surface of the protein are substituted, deleted or inserted in a region of the beta sheet accessible to a solvent or to a binding partner.

11. (Amended) Protein according to [one or more of the preceding claims, characterized in that] claim 1, wherein, amino acids exposed on the surface are substituted, deleted or inserted in a β -sheet structure of a domain or a subunit of the protein.

12. (Amended) Protein according to [one or more of the preceding claims, characterized in that] claim 1, wherein, it is a gamma-II-crystalline which has been obtained by substitution, deletion or insertion of one or more of the amino acids Lys 2, Thr 4, Tyr 6, Cys 15, Glu 17, Ser 19, Arg 36 and Asp 38 in gamma-II-crystalline.

13. (Amended) Protein according to [one or more of the preceding claims, characterized in that] claim 1, wherein, amino acids exposed on the surface of the protein have been substituted, deleted or inserted in the beta sheet such that it has antibody-like binding properties or an enzymic (catalytic) activity.

14. (Amended) Protein according to Claim 12 [or 13, characterized in that] wherein it has binding specificity for estradiol or the conjugate thereof, BSA- β -estradiol-17-hemisuccinate.

15. (Amended) Protein according to [one or more of the preceding claims, characterized in that] claim 1, wherein, it has binding specificity for estradiol or the

conjugate thereof, BSA- β -estradiol-17-hemisuccinate and has the amino acid sequence SEQ ID NO. 19 or SEQ ID NO. 21.

16. (Amended) Protein according to [one or more of the preceding claims, characterized in that] claim 1, wherein, it is combined with other proteins or non-protein substances.

17. (Amended) DNA coding for a protein according to [one or more of the preceding claims] claim 1.

19. (Amended) Prokaryotic or eukaryotic vectors or cells comprising a DNA or RNA according to Claim 17 [or 18] or parts thereof coding for functional regions of the protein.

20. (Amended) Method for preparing a protein according to [one or more of the preceding claims] claim 1, comprising the following steps:

- a. Mutagenesis of the DNA coding for a protein with beta-sheet structure in those regions which code for at least two beta strands, exposed on the surface, of a beta sheet exposed on the surface;
- b. Expression of the mutants obtained in step (a) in a suitable expression system; and
- c. Selection and isolation of mutants having the desired binding properties and/or the desired catalytic activity; optionally
- d. Expression and purification of the beta sheet-mutated proteins.

21. (Amended) Method according to Claim 20, [characterized in that] wherein the mutagenesis comprises a substitution, deletion or insertion of specific amino acid positions (site-specific mutagenesis) or non-specific amino acid positions (random mutagenesis) in the beta sheet.

22. (Amended) Method according to [one or more of the preceding claims, characterized in that] claim 20, wherein, the mutants in step b) are expressed in prokaryotic or eukaryotic cells, in a cell-free system as a complex with ribosomes or on the surface of plant or animal cells, yeast cells or phages, viruses or bacteria.

23. (Amended) Method according to [one or more of the preceding claims, characterized in that] claim 20, wherein mutants having the desired binding properties are selected by contacting these mutants with the binding partner and isolating those mutants having the desired binding affinity.

24. (Amended) Method according to [one or more of the preceding claims, characterized in that] claim 20, wherein mutants having the desired catalytic properties are selected by contacting these mutants with their substrate and isolating those mutants having the desired catalytic activity.

25. (Amended) Use of a protein according to [one or more of the preceding claims] claim 1 in diagnostics and therapy, in cosmetics, bioseparation and biosensors and reduction of harmful substances.

DESIGN OF BETA-SHEET PROTEINS WITH SPECIFIC BINDING PROPERTIES

AMENDED CLAIMS

1. Protein with beta-sheet structure,
characterized in that
amino acids exposed on the surface in at least two β -strands exposed on the surface of at least one beta sheet exposed on the surface are specifically substituted, deleted or inserted, such that the protein has new specific antigen binding properties or a new catalytic activity or new fluorescence properties.
2. Protein according to Claim 1,
characterized in that
it is included in the group consisting of crystallines, spherulines, heat shock proteins, cold shock proteins, β -helix proteins, lipocalins, serpins, fibronectins or transcription factors or is GFP, NGF, tendamistat or lysozyme.
3. Protein according to Claim 1 or 2,
characterized in that,
amino acids exposed on the surface in three beta strands exposed on the surface are substituted, deleted or inserted.
4. Protein according to Claim 1 or 2,
characterized in that,
amino acids exposed on the surface in four or more beta strands exposed on

the surface are substituted, deleted or inserted.

5. Protein according one or more of the preceding claims, characterized in that amino acids exposed on the surface in at least two beta strands in at least two beta sheets are substituted, deleted or inserted.
6. Protein according to one or more of the preceding claims, characterized in that, amino acids exposed on the surface in three beta strands in two antiparallel beta sheets are substituted, deleted or inserted.
7. Protein according to one or more of the preceding claims, characterized in that it is a crystalline of vertebrates, preferably rodents, birds or fish.
8. Protein according to one or more of the preceding claims, characterized in that, it is an alpha-, beta- or gamma-crystalline.
9. Protein according to one or more of the preceding claims, characterized in that, it is a gamma-II-crystalline protein.
10. Protein according to one or more of the preceding claims, characterized in that amino acids exposed on the surface of the protein are substituted, deleted or inserted in a region of the beta sheet accessible to a solvent or to a binding partner.
11. Protein according to one or more of the preceding claims, characterized in that, amino acids exposed on the surface are substituted, deleted or inserted in a β -sheet structure of a domain or a subunit of the protein.

12. Protein according to one or more of the preceding claims, characterized in that,
it is a gamma-II-crystalline which has been obtained by substitution, deletion or insertion of one or more of the amino acids Lys 2, Thr 4, Tyr 6, Cys 15, Glu 17, Ser 19, Arg 36 and Asp 38 in gamma-II-crystalline.
13. Protein according to one or more of the preceding claims, characterized in that,
amino acids exposed on the surface of the protein have been substituted, deleted or inserted in the beta sheet such that it has antibody-like binding properties or an enzymic (catalytic) activity.
14. Protein according to Claim 12 or 13, characterized in that
it has binding specificity for estradiol or the conjugate thereof, BSA- β -estradiol-17-hemisuccinate.
15. Protein according to one or more of the preceding claims, characterized in that,
it has binding specificity for estradiol or the conjugate thereof, BSA- β -estradiol-17-hemisuccinate and has the amino acid sequence SEQ ID NO. 19 or SEQ ID NO. 21.
16. Protein according to one or more of the preceding claims, characterized in that,
it is combined with other proteins or non-protein substances.
17. DNA coding for a protein according to one or more of the preceding claims.
18. RNA derived from the DNA according to Claim 17.
19. Prokaryotic or eukaryotic vectors or cells comprising a DNA or RNA according to Claim 17 or 18 or parts thereof coding for functional regions of the protein.

20. Method for preparing a protein according to one or more of the preceding claims, comprising the following steps:
- a. Mutagenesis of the DNA coding for a protein with beta-sheet structure in those regions which code for at least two beta strands, exposed on the surface, of a beta sheet exposed on the surface;
 - b. Expression of the mutants obtained in step (a) in a suitable expression system; and
 - c. Selection and isolation of mutants having the desired binding properties and/or the desired catalytic activity; optionally
 - d. Expression and purification of the beta sheet-mutated proteins.
21. Method according to Claim 20, characterized in that the mutagenesis comprises a substitution, deletion or insertion of specific amino acid positions (site-specific mutagenesis) or non-specific amino acid positions (random mutagenesis) in the beta sheet.
22. Method according to one or more of the preceding claims, characterized in that, the mutants in step b) are expressed in prokaryotic or eukaryotic cells, in a cell-free system as a complex with ribosomes or on the surface of plant or animal cells, yeast cells or phages, viruses or bacteria.
23. Method according to one or more of the preceding claims, characterized in that mutants having the desired binding properties are selected by contacting these mutants with the binding partner and isolating those mutants having the desired binding affinity.

24. Method according to one or more of the preceding claims, characterized in that mutants having the desired catalytic properties are selected by contacting these mutants with their substrate and isolating those mutants having the desired catalytic activity.
25. Use of a protein according to one or more of the preceding claims in diagnostics and therapy, in cosmetics, bioseparation and biosensors and reduction of harmful substances.

ABSTRACT

The present invention describes novel beta-sheet proteins having specific binding properties and catalytic properties and also methods for preparing these proteins.

P12389

Design of beta-sheet proteins with specific binding properties

The present invention relates to novel beta-sheet proteins with new or altered specific binding properties or a new or altered catalytic activity or new or altered fluorescence properties and also to methods for preparing proteins modified in such a way.

Antibodies and derivatives thereof are used in many areas of human and veterinary therapy, diagnostics and monitoring. One problem of utilizing the naturally occurring antibodies is the preparation thereof. The antibodies are still produced in an animal cell culture system, which is a very costly method. In some applications such as, for example, preparation of fusion proteins or a therapeutic use which requires rapid blood clearance and good tissue penetration, the size of naturally occurring antibody molecules represents another problem (Colcher et al., 1998). Recombinant antibody molecules such as scFvs (Bird et al., 1988), Miniantibodies (Pack and Plückthun, 1992) or bispecific antibodies (Holliger and Winter, 1993) are mainly composed of just the antigen-binding domains of the antibodies (VH and VL). Owing to their considerably reduced size, they show improved tissue penetration and are also better suited for fusions with other proteins than complete antibodies. Compared with the latter, though, recombinant antibody fragments are often more unstable, have low affinities and are difficult to prepare in recombinant form, owing to the disulphide bridges to be formed. Methods for stabilization and improved affinity of the recombinant antibody fragments include, inter alia testing various linker peptides and introduction of disulphide linkages (Glockshuber et al., 1990, Cumber et al., 1992, Brinkmann, 1997).

The sequence and length of the linker peptides can influence both the stability against proteases and the affinity of the antibody fragments (Pantoliano et al., 1991). The introduction of additional disulphide linkages into the conserved framework regions of the

variable domains can lead to increased resistance to heat (Young et al., 1995) and denaturing agents and to increased yields in heterologous expression. In general, however, many scFvs show low stability and tend to aggregate already at 37°C. The instability may also be caused by using the common Fv-fragment cloning primers which can introduce new destabilizing mutations. The antibody fragments are produced in the bacterial system mainly by exporting into the periplasmic space, and optimizations regarding the redox state and simultaneous expression of foldings helpers are possible here, too.

It is an object of the present invention to provide novel proteins having new or altered binding properties, for example antibody-like properties, but, at the same time, do not display the above-described disadvantages of complete or recombinant antibody molecules.

It is a further object of the present invention to provide proteins which display new or altered enzymic or catalytic properties.

It is another object of the present invention to generate methods for forming the abovementioned proteins.

The objects mentioned above are achieved by a protein having the features characterized in Claim 1. A method for preparing the proteins of the invention ensues from Claim 21. Preferred embodiments of the invention ensue from the subclaims and the description below.

Alteration of the surface of a beta-sheet protein generates novel binding properties previously not present in the protein. These binding properties are generated by mutagenesis of a beta-sheet region. In spite of the *de novo* binding properties, the novel beta-sheet proteins are similar to the starting proteins with respect to structure and stability. Starting proteins for designing the novel binding molecules are proteins with a predominant beta-sheet structure such as, for example, gamma-crystalline, a structural protein of the eye lens. Based on the crystal structure, regions and amino acids in the beta-sheet of the starting proteins, which are exposed on the surface and thus accessible to the solvent or possible binding partners, are selected, for example, by means of computer analyses. Using genetic engineering methods, these regions or amino acid positions are mutagenized in the gene coding for the starting protein. Thus, a multiplicity of mutated genes (bank or library) coding for the different beta-sheet proteins mutants are prepared at the DNA level. Mutants having

novel, desired binding properties are isolated with the aid of a suitable selection system such as, for example, the phage display system. In phage display, all protein mutants produced are exposed on the surface of bacteriophages (phage display library). These recombinant phages are studied with respect to their binding to the desired target molecules. Phages which expose on their surface beta-sheet mutants with specific binding to the target molecule are concentrated by repeated screening and isolated. Genes coding for binding beta-sheet mutants are obtained from the phages and expressed in a suitable expression system such as, for example, *E. coli*. Using the method described, it is surprisingly possible to prepare specifically binding proteins from beta-sheet proteins having no specific binding properties whatsoever, and mutants having the desired specificity are isolated from the library by applying a suitable screening method. Depending on the properties of the starting proteins, the beta-sheet mutants produced using the system described have advantages regarding size, stability and functionally active production in the heterologous, preferably bacterial, system, compared with, for example, antibodies and recombinant antibody fragments. These improved properties of the novel beta-sheet mutants make it possible to replace, for example, antibodies, recombinant antibody fragments of catalytic antibodies and to open up completely new application areas.

For example, the problems with antibodies, as illustrated above, can be solved according to the invention by designing proteins which have in each case specific binding properties and high stability against low pH, denaturing agents and elevated temperature, i.e. which withstand conditions under which antibodies are unstable. Generating proteins with beta-sheet structure and antibody-like binding properties, however, is only one possible field of application of the present invention. Further possible applications are opened up, for example, by generating beta-sheet proteins with new catalytic properties, for example resistance properties and fluorescent properties. An example of a protein whose fluorescent properties can be altered is GFP. The small proteins which are by nature highly stable are particularly suitable for the designing. Alteration of their surface generated, according to the invention and by way of example, new specific binding properties in the protein, with stability being retained.

A possible class of stable proteins, which was selected according to the invention and by way of example, is the crystallines. Crystallines which are the structural proteins of the eye lens are usually not subjected to cellular turnover and, consequently, have also extraordinary

stability properties (Mandal et al., 1987, Rudolph et al., 1990). Gamma-crystallines, a class of crystallines in vertebrates, are monomeric proteins with a molecular mass of approximately 22 kDa. The main structural motif of the gamma-crystallines is the antiparallel beta-sheet (Hazes and Hol, 1992, Richardson et al., 1992, Hemmingsen et al., 1994). Gamma-crystallines consist of two very similar globular domains, an N- and a C-terminal domain, which are linked to one another by a V-shaped linker peptide. The folding pattern characteristic for gamma-crystallines („greek-key“ motif Slingsby, 1985, Wistow and Piatigorsky, 1988) is the most likely reason for the considerable thermostability and stability against denaturing agents (Mandal et al., 1987). Gamma-II-crystalline from calf eyes is a 21 kDa protein with, for its size, unusually many (7) cysteines which are in the reduced state under physiological conditions.

In its properly folded state, gamma-II-crystalline has no binding properties whatsoever. The inventive alteration (mutagenesis) of a selected solvent-exposed region of this protein, which consists of the beta-sheet structural motif, surprisingly resulted in alteration of the surface structure and charge pattern of the protein and thus in generation of new binding properties. In this connection, only regions or amino acid positions whose involvement in preserving the structure of the protein is insignificant were reacted. Mutagenesis of small beta-sheet proteins (Riddle et al., 1997) has shown that a high percentage of the protein is capable of forming the native beta-sheet structure correctly, despite considerable changes in the sequence.

Attempts at mutating particular protein regions with the aim of isolating molecules having improved or new binding properties exist already for recombinant antibody fragments (Nissim et al., 1994, de Kruif et al., 1995), for proteins with established binding properties (receptors, inhibitor proteins, DNA-binding proteins) and for peptide libraries (Cortese et al., 1995, Haaparanta and Huse 1995, McConell et al., 1996). In the case of antibodies, only the antigen-binding domains which are present as loop regions are mutagenized. This is likewise the case for most other proteins such as, for example, tendamistat (McConell and Hoess, 1995) or cytochrome b_{562} (Ku and Schultz, 1995). Here too, loop regions are mutagenized. Examples of mutageneses in alpha-helices are the Z-domain of protein A (Nord et al., 1997) and the zinc-finger domain CP-1 (Choo and Klug, 1995). The previous mutageneses merely altered the specificity of the binding and always started from proteins with already established binding properties. A protein without binding properties was never used, nor was

A suitable system for isolating mutagenized beta-sheet proteins with *de novo* binding properties is the phage display system. This system makes possible very efficient screening of a large repertoire of protein variants for specific binding properties (Smith, 1985). In this connection, a protein variant is in each case presented on the surface of a filamentous phage and can interact with the target molecules immobilized on a solid phase. Proteins binding to the target molecule can be obtained by eluting the phages. After isolating the phage DNA, the DNA sequence of the specifically binding protein variants can be determined. In addition to the phage display system, it is also possible to apply other selection systems such as, for example, bacterial surface display (Stahl and Uhlen, 1997) or ribosome display (Hanes et al., 1997).

Using the above-described invention, it is surprisingly possible to alter, for example, the very stable beta-sheet protein gamma-II-crystalline by targeted, site-specific mutagenesis in the beta-sheet on the surface such that a protein with specific binding properties is generated from the non-binding protein. Randomizing eight amino acid positions thus leads, for the first time, to mutagenesis in a scaffolding molecule within a relatively rigid region of the protein. Thus a protein species which is „antibody-like“ with respect to its specific binding properties is prepared from the beta-sheet protein gamma-II-crystalline. Gamma-II-crystalline or other small stable beta-sheet proteins can generally be used in the described method as novel scaffolding molecules for designing novel binding properties. The modelled beta-sheet proteins can replace, for example, recombinant antibodies in various applications. Due to their relatively small size (20 kDa), they are suited as fusion partners for other functional proteins (preparation of multifunctional proteins). Further possible uses are in gene therapy in which they can be employed as modules for cell-specific targeting of gene-therapy vectors and in intracellular immunization. Furthermore, beta-sheet mutants with catalytical properties can be used in enzyme application areas. The stability of the novel binding proteins makes additionally possible applications which cannot be carried out at present using recombinant antibodies, for example in human and veterinary medical diagnostics and therapy and in

biosensor and bioseparation methods. Further fields of application are generally the pharmaceutical and cosmetic industries and the analysis and removal of harmful substances.

In the following, some preferred embodiments of the invention are described.

The proteins with beta-sheet structure, selected for mutagenesis according to the invention, have either no binding properties or no catalytic or enzymic activity or fluorescence properties or their activity, fluorescence properties or binding properties are such that an alteration, in particular improvement, is desirable.

Proteins with beta-sheet structure are known. An example of a protein class with beta-sheet is the crystallines, in particular alpha- beta- and gamma-crystallines. It is in principle possible to use crystallines from all kinds of animals, for example from vertebrates, rodents, birds and fish. Further examples of proteins which have beta-sheet structure and can be mutagenized according to the invention are: spherulins, heat shock proteins, cold shock proteins, beta-helix proteins, lipocalins, certins or transcription factors, fibronectins, GFP, NGF, tendamistat or lysozyme. For example, individual subunits or domains of the said proteins, for example crystallines, which have beta-sheet structure, are mutagenized according to the invention.

Among the crystallines, particular preferred mention must be made of gamma-crystalline for which it was possible, according to the invention and by way of example, to demonstrate that the beta-sheet structure thereof can be modified, i.e. mutagenized, such that new specific binding properties or new catalytic activities which are comparable to, for example, an antibody molecule are formed. An example of a gamma-crystalline is gamma-II-crystalline.

Examples of beta-helix proteins can be found, inter alia, in Jenkins J. et al., J. Struct. Biol. 1998, 122 (1-2): 236-46, Pickersgill, R. et al., J. Biol. Chem. 1998, 273 (38), 24600-4 and Raetz C.R. et al., Science 1995, 270 (5238), 997-1000.

The beta-sheet structure is defined by being essentially sheet-like and almost completely flat. In contrast to alpha-helices which are formed by a continuous part of the polypeptide chain, beta-sheets may be composed of various regions of the polypeptide chain. This makes it possible for regions which are relatively far apart in the primary structure to be located right next to one another. A beta-strand is typically 5-10 amino acids in length and is almost

completely flat. The beta-strands are so close to one another that hydrogen bonds form between the C=O group of one and the NH group of the other strand and vice versa. Beta-sheets may be composed of a plurality of strands and have a sheet-like structure. The C-alpha atom is located alternately above or below the sheet-like plane. The amino acid side chains follow this pattern and are thus orientated alternately upwards and downwards. Depending on the orientation of the beta-strands, a distinction is made between parallel and antiparallel sheets. According to the invention, both can be mutagenized and used for preparing the claimed proteins.

For mutagenesis of the beta-sheet structure, those beta-sheet regions in the protein, which are close to the surface, are selected. An amino acid exposed on the surface can be identified on the basis of the available X-ray crystal structure. If no crystal structure is available, it is possible by means of computer analysis to try to predict beta-sheet regions exposed on the surface and accessibility of individual amino acid positions on the basis of the available primary structure (www.embl-heidelberg.de/predictprotein/predictprotein.html) or to model the 3D protein structure (www.expasy.ch/swissmo/SWISS-MODEL.html) and thus to obtain information about amino acids possibly exposed on the surface.

However, beta-sheet mutageneses for which a time-consuming preselection of the amino acid positions to be mutagenized can be dispensed with are also possible. Those DNA regions which code for the beta-sheet structures are isolated from their DNA environment, subjected to a random mutagenesis and subsequently re-integrated into the DNA coding for the protein, from which they have been removed previously. This is followed by a selection method for mutants having the desired binding properties and/or catalytic properties and/or fluorescence properties.

In another embodiment of the invention, the beta-sheet regions close to the surface are, as already described above, selected and the amino acid positions to be mutagenized are identified within these selected regions. These amino acid positions selected in this way can then be mutagenized at the DNA level either targeted, i.e. a codon coding for a particular amino acid is replaced by a codon coding for a different, previously selected specific amino acid, or this exchange is carried out within the framework of a random mutagenesis, with the amino acid position to be exchanged being defined but not the codon coding for the new, hitherto undefined amino acid.

Amino acids exposed on the surface are accessible to the surrounding solvent. If the accessibility of amino acids in a protein is more than 8% compared with the accessibility of the amino acid in the model tripeptide Gly-X-Gly, these amino acids are called amino acids exposed on the surface. These protein regions or individual amino acid positions are also preferred binding sites for possible binding partners which are to be selected for according to the invention. The binding partners may be, for example, antigens or substrates or substrate-transition-state analogues.

According to the invention, it is possible to mutagenize virtually all proteins which display beta-sheet structures located on the surface and accessible to a solvent or a binding partner. To this end, suitable proteins are mainly those which are particularly stable, i.e. resistant to denaturation, for example, or sufficiently „small“.

„Mutagenization“ means according to the invention the alteration of one or more amino acids exposed on the surface in the polypeptide chain with beta-sheet structure. This includes, for example, amino acid substitutions in which an amino acid with particular properties with respect to its polarity, charge, solubility, hydrophobicity or hydrophilicity is replaced by an amino acid with a different property, thus for example a non-polar, hydrophobic amino acid by a polar amino acid, a negatively charged amino acid by a positively charged amino acid, etc. The term „mutagenization“ also comprises insertions and deletions of one more amino acids. A precondition is that the mutations comprise amino acids exposed on the surface in at least two beta-strands exposed on the surface of at least one beta-sheet exposed on the surface. The mutations are preferably and specifically introduced at individual amino acid positions in the beta-sheet or in selected regions of the beta-sheet. Mutagenizations may be present in one region or in a plurality of regions of the beta-sheet structure. The alterations may comprise adjacent amino acids or amino acids which are relatively far apart in the beta-sheet. The alterations may also comprise amino acids in various beta-sheets, i.e. in more than one beta-sheet. The insertions, deletions or substitutions of one or more amino acids are located in at least two beta strands exposed on the surface of at least one beta-sheet exposed on the surface. In this connection, it is possible to substitute, delete or insert one or more amino acids in one beta strand exposed on the surface, i.e. one beta strand exposed on the surface can have a plurality of mutations, if at least two beta strands exposed on the surface are mutated. In a further embodiment, in each case one beta-strand exposed on the

According to the invention, it is preferred, for example, that two or three beta-strands exposed on the surface are mutagenized. According to the invention, it is also possible that four or more beta-strands exposed on the surface are mutagenized. Furthermore, it is possible that at least two beta-strands in at least two beta-sheets are mutagenized, with preference being given to mutagenesis of three beta-strands in two antiparallel beta-sheets.

The mutations are carried out such that the beta-sheet structure is retained. In general, mutagenesis takes place on the outside of a stable beta-sheet region exposed on the surface of the protein. It comprises both site-specific and random mutagenizations. Site-specific mutageneses which comprise a relatively small region in the primary structure (approx. 3-5 amino acids) can be carried out using the commercially available kits from Stratagene (QuickChange) or Bio-Rad (Muta-Gene phagemid in vitro mutagenesis kit) (cf. US-A-5,789,166; US-A-4,873,192).

If larger regions undergo site-specific mutagenesis, a DNA cassette has to be prepared, and the region to be mutagenized is obtained by assembling oligonucleotides containing the mutated and the unaltered positions (Nord et al., 1997; McConell and Hoess, 1995). Random mutageneses can be introduced by propagating the DNA in mutator strains or by PCR amplification (error-prone-PCR) (e.g. Pannekoek et al., 1993). In this case, a polymerase with increased error rate is used. In order to increase the extent of the introduced mutagenesis or to combine different mutations, it is possible to combine the mutations in the PCR fragments by means of DNA shuffling (Stemmer, 1994). The review by Kuchner and Arnold (1997) provides an overview of these mutagenesis strategies for enzymes. In order to

The DNA molecules obtained in the mutagenesis step are expressed in a suitable expression system. Preference is given to those expression systems which facilitate subsequent selection and isolation of mutants having the desired binding properties and/or the desired catalytic or enzymic activity. Such expression vectors and expression systems are known to the skilled worker and have been described already in more detail above. Of course, it is also possible to use other expression systems which allow inventive selection for mutants with specific properties or activities.

The invention includes the mutagenized proteins, DNA molecules, RNA molecules derived thereof and functional parts thereof which code for a protein which has a mutagenized beta-sheet structure and is capable of binding to a desired binding partner in a new or altered manner or which can have a new or altered catalytic activity for a substrate or new or altered fluorescence properties. The term „functional parts“ relates to subunits, domains and epitopes of the protein with beta-sheet structure, which have been mutagenized according to the invention and possess the desired binding properties and activities or are partly responsible therefor.

When selecting for desired binding properties, the mutated proteins or functional parts thereof are contacted with their binding partners. Suitable detection methods select mutants having the desired binding properties.

Catalytic activity can be selected for in several ways:

Coupling of transition-state analogues to a solid phase and selecting the mutant library for the said analogues. These substances are analogues to transitional states of the substrate, which typically form during enzymic conversion of a substrate to the product (substrate-transition-state product). For this, however, the transition state of the substrate must be known. It is also possible to carry out a screening for substrate binding.

Cloning of the mutants into a bacterial expression system and plating of the recombinant bacteria for forming individual colonies. The mutated protein can be expressed in the bacteria by adding inducers (e.g. IPTG) to the nutrient medium. The nutrient medium must furthermore contain the substrate whose conversion is to be screened for. The substrate must form an identifiable, e.g. coloured, product during conversion. Those bacteria which express a mutant converting the substrate in the nutrient medium require a different colour. An example would be the screening for beta-galactosidase activity and conversion of X-Gal (blue staining) (Zhang et al., 1997).

Apart from the colour formation variant, it would also be possible, to select, for example, protein mutants which mediate a new resistance (addition of antibiotics to the nutrient medium) or which make possible growth on minimal nutrient media on which the „normal“ bacterium will not grow. It is possible here to make use of the selective growth advantage of the bacteria having the new protein mutant (Cramer et al., 1997).

For example in bacteria, obtaining the supernatant and testing for the desired enzymic activity to be selected (You and Arnold, 1996). The present invention thus solves the problem of generating proteins having new binding properties or new catalytic properties by mutagenizing proteins with beta-sheet structures in this structural motif. Those proteins are selected for, which possess the desired new or altered, preferably improved binding properties or the desired new or altered, preferably improved, enzymic or catalytic activities. The system of the invention even makes it possible to alter beta-sheet proteins which have no binding properties or no enzymic properties such that, after mutagenization in the beta-sheet, they acquire binding properties or catalytic properties.

According to the invention, „binding properties“ means, for example, the specific affinity of an antigen for an antibody. After the mutagenesis has been carried out according to the invention, the beta-sheet protein thus possesses antibody-like properties and combines the advantages of the high binding specificity of an antibody with the advantageous stability properties of a beta-sheet protein. The beta-sheet proteins with antibody-like properties, prepared according to the invention, may also possess a catalytic function.

However, the solution proposal according to the invention makes it also possible to generate proteins with beta-sheet structure, which have new or altered catalytic activities. The alteration of other protein properties, for example the fluorescent properties of GFP, would also be possible.

According to the invention, alteration of the binding properties, the catalytic activity or the fluorescence properties means both a deterioration and an improvement in the said properties, with an improvement being preferred.

According to the invention, a „protein having a new specific property“ or „having a new catalytic activity“ means a protein which previously has not had any specific binding property or catalytic activity and now has a specific binding property or a catalytic activity or a combination of both, due to the specific mutagenization of amino acids exposed on the surface in at least two beta-strands exposed on the surface of at least one beta-sheet exposed on the surface. However, this also includes proteins which already had a specific binding property or a catalytic activity prior to mutagenization and, after mutagenization in the beta-sheet, possess another, additional specific binding property and/or catalytic activity. It

is, of course, also possible that a protein with a specific binding property now has a catalytic activity or vice versa.

The invention furthermore comprises those proteins which already possess a specific binding property and/or an enzymic or catalytic activity and/or fluorescence properties and which, after mutagenization of amino acids exposed on the surface in at least two beta-strands exposed on the surface of one or more beta-sheets exposed on the surface, obtain an improvement in, or, in more general terms, and alteration of their specific binding properties and/or their catalytic activity and/or their fluorescence properties.

In this respect, the method of the invention and the proteins prepared thereby also differ from proteins and methods from the prior art, in which the beta-sheet structure was altered by random mutagenizations which were not directed towards the beta-sheet structure but towards the entire protein and which were in particular not targeted towards amino acids exposed on the surface in at least two beta-strands exposed on the surface of at least one beta-sheet exposed on the surface or which related to such amino acids exposed on the surface.

In a preferred embodiment of the invention, which will be described by way of example below, gamma-crystalline, as in the example of a protein with beta-sheet structure, was chosen as starting point for the mutagenesis. To this end, first amino acid positions exposed on the surface were selected through structural studies and mutagenized by mutagenization methods known per se. The mutants obtained were expressed in a suitable, likewise known expression system. The selection was directed towards those mutants whose amino acids exposed on the surface in the beta-sheet of the gamma-crystalline showed specific binding towards the antigen BSA-estradiol 17-hemisuccinate. Although a plurality of mutants having the desired binding property were isolated, only one carries the expected amino acid exchanges. Thus, an antibody-like non-immunoglobulin molecule was obtained, which is based on the starting protein gamma-crystalline.

The method of the invention makes it possible to prepare an indeed enormous number of mutants. Mutagenesis of just eight amino acid positions makes it possible to form 2.6×10^{10} different protein species which can be analysed for the desired binding properties and catalytic activities.

The mutated genes obtained can be propagated in suitable systems and the proteins can be expressed. Suitable expression systems are prokaryotic or eukaryotic systems. The DNA coding for the mutated protein is transferred, for example, into a suitable vector, for example into an expression vector, and introduced into a host cell by transformation, transfection or infection. The linkage to regulatory sequences which specifically control expression of the heterologous mutated DNA is advantageous, of course.

The invention, described in general terms above, is illustrated in more detail below on the basis of an exemplary embodiment and the attached drawings. The example is to be understood as a possible form of the invention and the invention is not restricted to this particular embodiment.

Fig. 1: Oligonucleotides for assembling the gamma-crystalline mutants.

Fig. 2: Schematic representation of oligonucleotide assembling and subsequent PCR on streptavidin-loaded magnetic beads (MB). The positions marked with X indicate the randomized amino acid positions.

Fig. 3: Schematic representation of the amplification of the non-mutagenized region of gamma-II-crystalline.

Fig. 4: Oligonucleotides for amplifying the non-mutagenized region of gamma-II-crystalline.

Fig. 5: Schematic representation of the pCANTAB 5E- gamma-II-crystalline expression cassette. g3-SS: signal peptide sequence of the phage protein G3; E-tag: 11 amino acids for immunological detection; fd Gen 3: minor coat protein 3 of the filamentous phage M13.

Fig. 6: Polyclonal phage ELISA with concentrated phages after 3rd panning. The microtitre plates were coated either with the BSA-beta-estradiol 17-hemisuccinate conjugate or just with BSA as control. Shown next to one another are the binding of gamma-II-crystalline wild-type phages (GC-WT), of the phages from the starting library (GCUC-1) and of the phages concentrated by repeated panning (E-17 phages) to the particular antigen.

Fig. 7: Partial DNA sequence of the BSA-estradiol-17-hemisuccinate-binding gamma-II-crystalline mutant 12A (Mu 12A) in phagemid pGCKT 8-3 and of gamma-II-crystalline wild-type (WT) in pCANTAB 5E respectively. The introduced cleavage sites Sfi I (5') and Bst EII (3') are indicated by italics and underlining. The codons of the randomized amino acid positions are in bold type.

Fig. 8: Derived amino acid sequences of the BSA-estradiol-17-hemisuccinate-binding gamma-II-crystalline mutant 12A (Mu 12A) and of gamma-II-crystalline wild-type (WT) after expression in the phagemids and removal of the signal peptide. The randomized amino acid positions are indicated by bold type and amino acids which have actually been exchanged are indicated by bold type and are underlined. Amino acids additionally introduced at the N-terminals via the Sfi I cleavage site and the C-terminal E-tag fusion are shown in italics and underlined.

Fig. 9: Sequence of the primers used for cloning Mu 12A and gamma-II-crystalline into vector pET-20b.

Fig. 10: Derived protein sequence of the BSA-estradiol-17-binding mutant 12A and of gamma-II-crystalline after expression in pET-20b. The randomized amino acid positions are indicated by bold type and amino acids which have actually been exchanged are indicated by bold type and are underlined. C-terminal amino acids additionally introduced via the cloning, including the 6 histidine are shown in italics and underlined.

Fig. 11: Concentration-dependent binding of mutant 12A to the BSA-beta-estradiol-17-hemisuccinate conjugate. The binding of the mutant (12A) and of gamma-II-crystalline (WT) to the conjugate (BSA-Estr. 17) and, as a control, to BSA was analysed.

Fig. 12: Stability of mutant 12A against the denaturing agent guanidine. The figure shows the emission maxima after incubating the purified mutant 12A and gamma-II-crystalline proteins with various concentrations of guanidine for various periods.

Fig. 13: Fluorescence emission spectrum of wild-type gamma-crystalline and mutant 12A in 50 mM Na phosphate, pH 6.5. The fluorescence signal (Fig. 13A) was measured at an excitation wavelength of 280 nm. The protein concentration was 100 µg/ml. Fig. 13B shows the absorbance spectra of the protein samples used for fluorescence measurement. The absorbance was determined in a cuvette with 1 cm path length.

EXAMPLE

Preparation of a gamma-crystalline mutant with specific binding to the hormone estradiol

The design of novel beta-sheet proteins with antigen-binding properties is shown on the basis of isolating a mutant of the bovine gamma-B-crystalline (gamma-II), which binds specifically to the hormone estradiol. Specific alteration of selected amino acid positions of a

beta-sheet exposed on the surface produced a novel stable protein with beta-sheet structure and specific binding properties. After selecting the beta-sheet region or amino acids suitable for mutagenesis, a site-specific mutagenesis was carried out at the DNA level, and in a phagemid a beta-sheet mutant library was prepared, which makes expression and subsequent selection for novel binding properties of the mutants in the phage display system possible. The isolated mutant was compared to the starting protein gamma-II-crystalline with respect to its new properties.

Selection of a suitable region for mutagenesis in gamma-crystalline

Based on the X-ray structure of gamma-II-crystalline (Wistow et al., 1983), the N-terminal domain of gamma-II-crystalline (Acc. M16894) was selected for mutagenesis. Eight amino acids in all, which form a continuous surface segment, were identified there. The selected amino acids are part of a beta-sheet and should not contribute substantially to preserving the structure. They are amino acid positions which are accessible to the solvent and thus also to possible binding partners. The eight amino acids Lys 2, Thr 4, Tyr 6, Cys 15, Glu 17, Ser 19, Arg 36 and Asp 38 comprise an area of approx. 6.1% of the total surface area of the protein.

Preparation of a DNA pool of mutated gamma-II-crystalline genes

The eight amino acid positions were randomized by site-specific mutagenesis. This makes it possible to produce 2.6×10^{10} different protein species. The region to be mutagenized was obtained at the DNA level by assembling individual oligonucleotides. This was followed by cloning into a phagemid constructed for selection in the phage display system.

Oligoassembling

For mutagenesis, 227 bp containing the 5' region of the gamma-crystalline mutants with the eight randomized amino acid positions and also suitable restriction cleavage sites were assembled on a solid phase. 10 individual oligonucleotides in all were used therefor, three of which contained the randomized amino acid positions (Fig. 1). During primer synthesis, the nucleotide mixture NN(T/G) was used at the eight positions to be mutagenized, resulting theoretically in 32 different codons at one position (cf. Nord et al., 1997). At the start of the

All oligonucleotides used for assembling were adjusted to a concentration of 100 pmol/ μ l. First, the primers GCLIE1B and GCLIE2P were assembled. For this, 36 μ l of washing and binding buffer (WB buffer: 1M NaCl, 10 mM Tris-HCl pH 7.5, 1 mM EDTA) were added to in each case 4 μ l of the primers and the mixture was incubated at 70°C for 5 min. After assembly of the two primers and further incubation at 70°C for 5 minutes, the primer mixture was slowly cooled to room temperature. 4 μ l of the GCLIE1B/GCLIE2P primer hybrids were mixed with 56 μ l of WB buffer and added to 300 μ g of the streptavidin-loaded MBs which had been washed beforehand with washing and binding buffer. Incubation at room temperature for 15 minutes was followed by washing the MBs with WB buffer and TE buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA). A primer linker fragment is added to the MBs coupled to the first primer hybrid, which fragment is prepared as follows: 4 μ l of primer GCLIB4P or GCLI5P are mixed with 36 μ l of 1 x ligation buffer from GIBCO BRL (50 mM Tris-HCl pH 7.6, 10 mM MgCl₂, 1 mM ATP, 1 mM DTT, 5% (w/v) polyethylene glycol-8000). After incubation at 70°C for 5 minutes, both mixtures are combined, incubated at 70°C for a further 5 min and cooled to room temperature. After adding 12 units of T4 DNA ligase (GIBCO BRL) and 8 μ l of 1 x ligation buffer, the reaction mixture is incubated at room temperature for 1 h. 12 μ l of this GCLIE3P/GCLIB4P/GCLI5P bridging fragment are admixed with 54 μ l of 1 x ligation buffer and 6 units of ligase, and the mixture is added to the washed MBs containing the first primer hybrid and incubated at room temperature for 1 h. After the ligation reaction, the MBs are washed twice with TE buffer and taken up in 64 μ l of 1 x ligation buffer containing 8 μ l of ligase. 8 μ l of the assembled primer mixture GCLIE6P/GCLIB7P, which primers have been assembled beforehand in analogy to those of GCLIB4P/GCLI5P, were then added to the MBs. The ligation was again carried out at room temperature for 1 h. After washing the MBs twice in TE buffer, 12 μ l of the 2nd bridging fragment GCLIB8P/GCLIE9P/GCLIE10 are added and the mixture is ligated for 1 h. The 2nd bridging fragment is prepared analogously to the first bridging fragment, GCLIE9P and GCLIE10 being assembled first and then ligated with GCLIB8P in the second step. The MBs with the immobilized primers are then again washed with TE buffer. The subsequent DNA-polymerase and ligase reaction fills in the gaps in the second strand. The MBs are incubated at 37°C for 30 min in the following buffer mixture:

52.5 μ l of H₂O, 6 μ l of buffer L from Boehringer (100 mM Tris-HCl pH 7.5, 100 mM MgCl₂, 10 mM dithioerythritol), 0.5 μ l of dNTPs (25 mM of each dNTP) and 1 μ l (2 units) of Klenow fragment (Boehringer). Washing the MBs twice with TE buffer is followed by the ligation reaction at room temperature for 1 h. A 100 μ l mixture contains 10 units of ligase. After two washing steps with TE buffer, the DNA strand non-covalently bound to the MBs is removed by treatment with 40 μ l of 0.1 M NaOH for 30 s, and the MBs are resuspended in 60 μ l of TE. The PCR for amplifying the library is carried out using the MBs as template. The PCR reaction mixture (50 μ l) is prepared as follows: 6 μ l of MBs, 5 μ l of 10 x PCR reaction buffer from Stratagene (100 mM KCl, 100 mM (NH₄)₂SO₄, 200 mM Tris-HCl pH 8.75, 20 mM MgSO₄, 1% Triton X-100, 1 mg/ml BSA), 1 μ l (2.5 units) of Pfu DNA polymerase (Stratagene), 0.5 μ l of dNTPs (25 mM of each dNTP), 0.35 μ l of GCLIE1B, 0.35 μ l of GCLIA11B and 36.8 μ l of H₂O. The PCR was carried out in 35 cycles with primer annealing at 55° for 1 min, a polymerase reaction at 72°C for 1.5 min, denaturation at 95°C for 1 min and a final polymerase reaction at 72°C for 5 min.

Preparation of phagemid pGCKT 8-3

Starting from phagemid pCANTAB 5E (PRAS kit from Pharmacia Biotech), a phagemid derivative for cloning the gamma-II-crystalline mutant band was thus constructed. The entire 3' region of gamma-II-crystalline (C-terminal domain) and the non-mutagenized 5' region were amplified by means of PCR using plasmid pGII (Mayr et al., 1994) as template and primers GCFORNOT and GCBACKSfiBst (Figs. 3, 4).

The Sfi I (GCBACKSfiBst) and Not I (GCFORNOT) cleavage sites introduced by the primers make insertion of the PCR product into phagemid (GCFORNOT) pCANTAB 5E possible. Together with the GCBACKSfiBst primer, a Bst EII cleavage site was additionally integrated into the gamma-crystalline gene, which allowed cloning of the mutated gamma-crystalline DNA fragments. *de novo* introduction of the cleavage site does not alter the amino acid sequence in gamma-II-crystalline. After sequencing, the PCR product was cloned as Sfi I/Not I fragment into phagemid Sfi I/Not I cut with pCANTAB 5E. The phagemid pGCKT8-3 constructed in this way was the starting point for preparing the gamma-II-crystalline phage display library.

Preparation of the gamma-crystalline mutant-library and cloning of wild-type gamma-II-crystalline

Phagemid pGCKT 8-3 was cut with Bst EII and Sfi I restriction enzymes and subjected to phosphatase treatment (shrimps phosphatase from USB). After the individual cleavages, the DNA was fractionated by gel electrophoresis, and the cleaved vector fractions were excised and isolated from the agarose gels by means of electroelution. Any further enzymatic treatment was preceded by phenol/chloroform extraction and precipitation of the DNA with glycogen. The DNA fragment pool which had been amplified by means of PCR and which contained the mutated region of gamma-II-crystalline was cleaved with Sfi I and Bst EII restriction enzymes. A total 440 ng of phagemid and 110 mg of PCR product were used for ligating the PCR products into the prepared pGCKT 8-3 phagemid. The ligations were carried out with a total 44 units of T4 DNA ligase (GIBCO BRL) in 20 µl mixtures at 16°C overnight. After inactivating the ligase at 70°C for 20 minutes, the ligation reactions were desalted by drop dialysis for 1 h. In each case 30 µl of electrocompetent *E. coli* TG 1 cells were transformed with in each case 15 µl of the dialysed ligations. The electrocompetent cells were prepared and transformed as described in the PRAS-kit manual. The transformed cells were created onto glucose- and ampicillin-(100 µg/ml) containing SOBAG plates (see PRAS-kit manual from Pharmacia-Biotech) and incubated at 30°C overnight. The GCUC-1 library prepared contained 250 000 original clones. The clones were washed off with 2 x YT medium (see PRAS-kit manual) containing 1% glucose and 20% glycerol, aliquoted and stored at -80°C. The amplification factor of the library was determined to 7×10^6 . The proportion of recombinant clones in the GCUC-1 library was 97%. Sequencing of randomly selected clones revealed that codons were used with the expected variants at the randomized amino acid positions. Expression rates of 30-60% were detected in the library by means of Western-blot analyses.

In control experiments, gamma-II-crystalline DNA was amplified using primers GCFORNOT (5' GAGTCATTCTGCGGCCGCATAAAAATCCATCACCCGTCTTAAAGAACC 3') and GCBACKSFI (5' CATGCCATGACTCGCGGCCAGCCGGCCATGGGGGAAGATCACTTTTTACGAGGAC 3') and plasmid pGII (Mayr et al., 1994) as template. After cleavage with Not I and Sfi I restriction endonucleases, the sequenced PCR product was cloned into the Sfi I/Not I phagemid likewise cut with pCANTAB 5E.

A phage display design and selection for novel binding properties

The commercially available phage display system PRAS from Pharmacia-Biotech was used for selecting gamma-crystalline mutants for binding properties. In the pCANTAB 5E (wild-type gamma-II-crystalline) and pGCKT 8-3 (gamma-crystalline mutants) phagemids used, the gamma-crystallines are fused N-terminally to the G3 signal peptide and C-terminally to an E-tag which makes immunological detection of the proteins possible (Fig. 5). Depending on the bacterial strain used, the *amber* stop codon after the E-tag is either recognized (*E. coli* HB 2151), and cleavage of the signal peptide is followed by secretion or overreading of the *E. coli* cell. After adding a helper phage, recombinant phages can be formed which expose the gamma-II-crystalline variants on their surface.

Optimization of cultivation conditions for the GCUC-1 library and gamma-II-crystalline wild-type phages

Under the cultivation conditions described in the PRAS manual, it was not possible to detect in any of the recombinant phages the expected fusion proteins (gamma-II-crystalline/protein 3) by means of Western-blot analyses. Only the addition of reduced glutathione (GSH) during phage formation altered the redox state in the periplasm of the bacterial cell and thus provided more favourable conditions for phage assembling. When using the gamma-II-crystalline clone, it was possible to detect recombinant phages carrying the fusion protein only with the addition of GSH. Increasing GSH concentration also increased the proportion of gamma-II-crystalline phages. The optimal GSH concentration was determined to 8 mM. One reason for poor gamma-crystalline expression on the phage surface in the absence of GSH could be the high proportion of reduced cysteines (7) in gamma-crystalline. When the partially unfolded gamma-crystalline enters the periplasm, it could, under the oxidative conditions prevailing there, misfold and form aggregates due to the formation of disulphide bridges. This could also suppress phage assembling. When using proteins with reduced cysteines in the phage display system, it may be possible to improve formation of recombinant phages generally by adding GSH.

Selection process using the GCUC1 phage display library

To screen the GCUC-1 library, all glass equipment used was sterilized at 220°C for 4 h and plastic material was sterilized with Helipur for 1 h. GCUC-1 library panning was carried out using BSA-beta-estradiol 17-hemisuccinate (Sigma) as antigen and microtitre plates (Maxisorp from NUNC) as solid phases. During the 3 rounds of panning, the stringency of the washing steps was increased. For the first cultivation, 100 ml of 2 × YT medium containing 2% of glucose and ampicillin (100 µg/ml) were inoculated with 50 µl of the GCUC-1 library. The bacteria grew at 37°C and 300 rpm to an OD₆₀₀ of 0.4. 800 µl of M13KO7 helper phage (1 × 10¹¹ pfu/ml, GIBCO BRL) were added to 10 ml of this bacterial culture. This was followed by incubation at 37°C for 30 min without and for a further 30 min with gentle agitation (50 rpm). The bacterial pellet was obtained by centrifugation at room temperature and 1 500 rpm (Sorvall SS 34 Rotor) for 20 min and taken up in 100 ml of 2× YT medium containing 8 mM GSH, 100 µg/ml ampicillin and 50 µg/ml Kanamycin. The recombinant phages were produced by overnight culturing at 30°C and 300 rpm. The supernatant containing the recombinant phages was obtained by two centrifugations at 10 800g for in each case 15 minutes and subsequent filtration (pore size 0.45µm). The phages were concentrated by adding 1/5 of PEG/NaCl solution (20% PEG-8000, 2.5 M NaCl) to the supernatant, incubating on ice for one hour and two centrifugations at 4°C and 3 300g for in each case 30 minutes. The phage pellet obtained was suspended in 4 ml of PBS pH 7.2, and remaining cell components were removed by centrifugation (10 min, 11 600 g, room temperature). For the selection process (panning), 1 ml of concentrated phages were mixed with 1 ml of a 6% strength BSA solution (6% BSA in PBS, pH 7.2) and incubated at room temperature for 10 min. In each case 100 µl of the phages treated in this way were added to the antigen-coated microtitre plate wells prepared as follows. NUNC-Maxisorp microtitre plates were coated with the antigen BSA-beta-estradiol 17-hemisuccinate. In each case 100 µl of antigen solution (100 µg/ml in PBS pH 7.6) were introduced into 10 wells in total. The wells coated at room temperature overnight were washed three times with PBS, pH 7.6. Free binding sites were saturated by filling the wells with a 3% strength BSA/PBS solution, pH 7.2, at room temperature for 2 h. Prior to adding the BSA-treated phages, the wells were washed twice with a PBS solution (pH 7.2). Panning was carried out by agitating the microtitre plate gently (20 rpm) for 30 minutes followed by incubation without shaking at room temperature for 90 minutes. Unspecifically bound phages were removed by washing 10 times with PBS, pH 7.2/0.1% Tween-20 and washing 10 times with PBS, pH 7.2. Bound

phages were eluted by adding in each case 100 μ l of 100 mM triethylamine (freshly prepared) per well and incubating at room temperature for 10 minutes. The base-eluted phages (1 ml) were neutralized by adding 500 μ l of 1 M Tris-HCl pH 7.4. 750 μ l of these phages were used for infecting 9 ml of TG-1 cells cultivated on minimal medium plates and having an OD₆₀₀ of 0.4-0.5. For this, the bacteria were incubated with the phages at 37°C for 30 min. It was possible to save phages which had bound particularly tightly and had not been removed from the microtitre plate by triethylamine treatment by direct infection of TG-1 cells. For this, in each case 100 μ l of the cultivated TG-1 cells were added to the wells. After incubating at 37°C for 30 minutes, the infected TG-1 cells were removed and combined with those from infection with the eluted phages. The infected bacteria were created onto 16x16 cm SOBAG plates and incubated at 30°C overnight. In each case 1 μ l of concentrated and eluted phages was used for determining the titre. The bacterial clones obtained were washed off the SOBAG plates with 12.5 ml of 2 x YT, 20% glycerol. The second and third pannings were carried out similarly to the first with the following changes. Phage cultivation was repeated using 20 μ l of the washed-off library in 20 ml of medium. 2 ml of the cultivated bacterial culture were used for infection with the helper phage (bacterial/phages weight ratio: 1/20). In the second panning the microtitre plates were washed first 15 times with PBS/Tween-20 and then 10 times with PBS and in the 3rd panning first 20 times with PBS/Tween-20 and then 10 times with PBS.

ELISA for checking concentration and specific binding

Concentration of the phages specifically binding to the antigen was detected using a polyclonal phage ELISA. In addition to the eluted phages, phages of the starting library GCUC-1 and of wild-type gamma-II-crystalline were assayed for comparison. NUNC-Maxisorp plates were coated with 100 μ l of BSA-estradiol17-hemisuccinate or BSA at a concentration of 2 μ g/ml of PBS pH 7.6 at room temperature overnight. 3 washings of the wells with PBS, pH 7.6 were followed by blocking with 3% dried milk powder (Glücksklee)/PBS, pH 7.2 at 37°C for 2 h and another (3) washings with PBS, pH 7.6. The non-concentrated recombinant phages isolated after phage cultivation were firstly blocked at room temperature for 1 h (1:1 mixture with 6% strength dried milk powder (Marvel)/PBS pH 7.6. 100 μ l of the blocked phages were applied per well and incubated at 37°C for 1 h.

Washing the wells in each case 3 times with PBS/Tween-20 and PBS was followed by incubation with the anti-M13 antibody-POD conjugate (Pharmacia-Biotech, dilution 1:5 000 in 3% Glücksklee/PBS) at 37°C for 1 h. After washing the plates, the enzyme-bound antibody was detected using 100 µl of Immuno-Pure-TMB substrate (Pierce). The colour reaction was stopped by adding 100 µl of 2M H₂SO₄ and extinction at 450 nm was determined. The result of the concentration of the phages binding to the BSA-estradiol conjugate, after the 3rd panning, is shown in Fig. 6.

Isolation and characterization of individual phages with specific binding to the conjugate

80 individual clones were selected from the bacterial clones obtained after the 3rd panning. Phages were isolated from the clones and assayed individually in the monoclonal phage ELISA with respect to their antigen binding. Individual bacterial clones were cultivated in 100 µl of 2 × YT medium containing 2% glucose and 100 µg/ml ampicillin in polypropylene microtitre plates (NUNC) with gentle agitation (100 rpm) overnight. 2 µl of these bacterial cultures were diluted 1:100 in the same medium and cultured at 100 rpm at 37°C to an OD₆₀₀ of 0.4. Phages were obtained as described for the selection process. Deep well polypropylene microtitre plates from TECAN were used for phage cultivation. For the ELISA, 200 µl of the phage supernatant obtained after centrifugation (not concentrated) were blocked with 40 µl of 6xPBS/18% at room temperature for 1 h. 30 out of 80 clones assayed showed significant binding of the recombinant phages to BSA -Estradiol-17 and not to BSA assayed in parallel. Phages with wild-type gamma-II-crystalline showed in a control experiment no binding to BSA-estradiol-17 whatsoever. 14 selected binding phages were sequenced using the IRD 800-labelled primers pCANR1LAB (5' CCATGATTACGCC-AAGCTTTGGAGCC 3') and GCLISEQ (5' CTGAAAGTGCCGGTGTGTTGC 3'). Only in one case, sequencing revealed a gamma-crystalline variant (Mu 12A) which was mutated exclusively in the eight randomized amino acid positions. A number of clones showed shifts in the reading frame and, although theoretically coding for a functional protein, had alterations which were not exclusively in the expected gamma-crystalline region. These frame shift mutants were not studied further.

Characterization of beta-sheet mutant 12A

Expression of the fusion protein Mu 12A-minor coat protein 3 on the surface of the recombinant phages and expression of Mu 12A in *E. coli* strain HB 2151 were detected by means of Western-blot analyses using the anti-G3P and anti-E-Tag antibodies (Pharmacia-Biotech), respectively. The DNA sequences of mutant 12A in phageimide pGCKT 8-3 and of gamma-II-crystalline wild-type are depicted in Fig. 7. The DNA sequence starts at the Sfi I cleavage site which is already present in the starting phageimide pCANTAB 5E and ends, in the case of pGCKT 8-3, at the Bst EII site newly introduced into the gamma-II-crystalline gene and, in the case of the gamma-II-crystalline wild-type gene, at the original sequence. Fig. 8 depicts the amino acid sequences derived therefrom. Codon randomization at amino acid position 36 does not change the amino acid arginine at this position. Computer modelling of mutant 12A shows that the amino acid exchanges do not cause large alterations in the protein structure compared with the starting protein. However, the net charge becomes more positive.

Expression of Mu 12A in pET-20b

In order to characterize mutant 12A in detail, the DNA was recloned into plasmid pET-20b (Novagen). The plasmid makes possible a high expression of the recombinant DNA in *E. coli* strain BL 21 and simple purification of the foreign proteins. Genes are expressed here without signal peptide and with a C-terminal fusion of 6 histidine residues. The DNAs of mutant 12A and of gamma-II-crystalline wild-type were amplified by means of PCR using the appropriate phageimide DNA and primers GC 20bback12A/GC for 20b for mutant 12A and GC 20bbackWT/GC for 20b for the wild-type (Fig. 9). The PCR fragments were cleaved with restriction endonucleases Nde I and Bam HI and cloned into vector pET 20b cut with Nde I/ Bam HI. Fig. 10 depicts the theoretical amino acid sequence of mutant 12A and of gamma-II-crystalline, respectively, after expression in pET-20b. The first 10 N-terminal amino acids of mutant 12A were confirmed by N-terminal protein sequencing.

Cultivation and purification of mutant and wild-type in pET-20b

In order to study the binding properties and stability of the mutant in detail, large amounts of mutant 12A and wild-type proteins were prepared. BL 21 cells were transformed with plasmids pET-20b/Mu 12A and pET-20b/Gamma-II-crystalline, respectively. The clones were cultivated by diluting a preculture 1:100 with LB medium/100 µg/ml ampicillin and agitating the culture at 200 rpm and 37°C up to an OD₆₀₀ of 0.5. Expression of the gamma-crystalline was induced by adding IPTG (final concentration 1 mM). Culturing was continued overnight at 30°C and 200 rpm. The bacteria cells were harvested by centrifugation at 4°C, 6 000rpm (Sorvall GS3 rotor) for 10 min. The cell pellet was suspended in 30 ml of 2 x PBS with addition of 150 µl of 200 mM PMSF and 10 µl of DNase (Boehringer). The cells were then disrupted twice using a Gaulin press at 800-1000 PSIG. The supernatant containing the soluble proteins was obtained after centrifugation of the cell suspension at 4°C and 20 000 rpm (Sorvall SS 34 rotor) for 1 h. The gamma-crystallines fused to 6 histidine residues were purified by affinity chromatography at 4°C. 8 ml of Ni-NTA were equilibrated with 50 ml of 2 x PBS/10 mM imidazole. The supernatant containing the soluble proteins was then slowly agitated with the equilibrated column material in a batch process on a roller shaker overnight. Introducing the suspension into a chromatography column was followed by washing with 2 x PBS/10 mM imidazole/300 mM NaCl. The bound protein was eluted with 2 x PBS/ 250 mM imidazole. DTT (final concentration 10 mM) was added to the eluted proteins. This was followed by 2 dialysis steps at 4°C for in each case 8 h: 1st with 100 mM Na phosphate buffer pH 6.0/ 1 mM EDTA/1 mM DTT and 2nd with 10 mM Na phosphate buffer pH 6.0/ 1 mM EDTA. The supernatant obtained after a final centrifugation (4°C, 30 min, 20 000 rpm in Sorvall SS 34 rotor) contained the purified protein (Mu 12A or Gamma-II-crystalline) which was used for binding studies and stability studies.

Specific binding of mutant 12A to the BSA-estradiol-17-hemisuccinate conjugate was assayed by carrying out an ELISA, with increasing concentrations of purified mutant 12A-His-Tag protein being used. Increasing amounts of gamma-II-crystalline wild-type (likewise with His-Tag) were used as control, and binding of both purified proteins to BSA was assayed. The concentration-dependant ELISA was carried out using NUNC-Tm plates. Antigen coating with the BSA-estradiol-17-hemisuccinate conjugate or with BSA was carried out at room temperature overnight. Coating was carried out with in each case 100 µl of antigen at a concentration of 20 µg/ml of PBS pH 7.6. After washing (2 x PBS pH 7.6) and

blocking the plates (3% Marvel/PBS at 37°C for 2 h), in each case 1-13 μ l of the protein stock solution (concentration 0.63 mg/ml) of purified Mu 12A or gamma-II-crystalline were introduced into a total 100 μ l of reaction solution (PBS, 3% Marvel, x μ l of protein) and incubated in the wells at 37°C for 2 h. The secondary antibodies used were the tetra-His antibody from Qiagen in a dilution of 1:3000 and the anti-mouse POD antibody (Sigma) in a dilution of 1:2000. The antibodies were diluted with a 3% strength Marvel/PBS solution and 100 μ l were added to the wells and incubated at 37°C for in each case 1 h. The substrate reaction was carried out as described for the polyclonal phage ELISA. The result of this ELISA in Fig. 11 shows clearly that increasing extinctions are measured only with increasing concentrations of mutant 12A. No increase was detected using gamma-II-crystalline. Likewise, no reaction with BSA was observed. This shows specific binding of mutant 12A compared with the starting protein.

Stability was studied by recording guanidine denaturation because of mutant 12A and of gamma-II-crystalline. For this purpose, the purified proteins were incubated at a final concentration of 20 μ g/ml with increasing concentrations of guanidinium at 20°C for one and three days. In total 15 guanidinium concentrations were adjusted in a range from 0 – 5.5 M in a 1 mM DTT/0.1 M Na phosphate buffer pH 6.0 solution. After one and three days, respectively, a 300-400 nm fluorescence emission spectrum of each mixture was recorded. The excitation wavelength was 280 nm. Fig. 12 depicts the emission maxima determined as a function of guanidinium concentrations. The stability of gamma-II-crystalline is higher than that of mutant 12A both after one day and after three days. However, compared with antibody molecules, the stability of mutant 12A is much higher.

Change in fluorescence properties of mutant 12A

Fluorescence spectra were recorded in order to test whether the fluorescence properties of mutant 12A have changed compared with wild-type protein. For this purpose, in each case 100 μ g/ml of wild-type protein or mutant 12A (in 50 mM Na phosphate, pH 6.0) were excited at 280 nm and fluorescence was measured in a wavelength range from 300 to 400 nm in a cuvette of 1 cm pathlength. The slit width was 5 nm both for excitation and for emission.

Mutant 12A and wild-type have an identical total number of fluorophores. However, sequence alterations in the mutant (Y -> K at Position 8 and C -> Y at Position 15) cause a change in the fluorescence signal. The difference in fluorescence intensity can be attributed to the fact that the tyrosine residues in positions 8 and 15, respectively, have different fluorescence properties.

References:

- Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S.-M., Lee, T., Pope, H. S., Riordan, G. S. and Whitlow, M. (1988): Single-chain antigen-binding proteins. *Science* 242, 423-426.
- Brinkmann, U., di Carlo A., Vasmatzis, G., Kurochkina, N., Beers, R., Byungkook, L. and Pastan, I. (1997): Stabilization of a recombinant Fv fragment by base-loop interconnection and VH-VL permutation. *J. Mol. Biol.* 268, 107-117.
- Choo, Y. and Klug, A. (1995): Designing DNA-binding proteins on the surface of filamentous phage. *Curr. Opin. Biotechnol.* 6, 431-436.
- Colcher, D., Pavlinkova, G., Beresford, G., Booth, B. J., Choudhury, A. and Batra, S. K. (1998): Pharmacokinetics and biodistribution of genetically-engineered antibodies. *Q. J. Nucl. Med.* 42, 225-241.
- Cortese R., Monaci, P., Luzzago, A., Santini, C., Bartoli, F., Cortese, I., Fortugno, P., Galfre, G., Nicosia, A. and Felici, F. (1995): Selection of biologically active peptides by phage display of random peptide libraries. *Curr. Opin. Biotechnol.* 6, 73-80.
- Cumber, J. A., Ward, E. S., Winter, G., Parnell, G. D. and Wawrzynczak, E. J. (1992): Comparative stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bisFvCys conjugate. *J. of Immunology* 149, 120-126.
- Glockshuber, R., Malia, M., Pfitzinger I. and Plückthun, A. (1990): A comparison of strategies to stabilize immunoglobulin Fv-fragments. *Biochemistry* 29, 1362-1367.
- Haaparanta T. and Huse W. D. (1995): A combinatorial method for constructing libraries of long peptides displayed by filamentous phage. *Mol. Diversity* 1, 39-52.
- Hanes, J. et al. (1997): *In vitro* selection and evolution of functional proteins by using ribosome display. *Proc. Natl. Acad. Sci. USA.* 94, 4937-42.
- Hazes, B. and Hol, W. G. J. (1992): Comparison of the hemocyanin β -barrel with other greek key β -barrels: possible importance of the „ β -zipper” in protein structure and folding. *Proteins: Struct., Funct. Gen.* 12, 278-298.
- Hemmingsen, J. M., Gernert, K. M., Richardson, J. S. and Richardson, D. C. (1994): The tyrosine corner: a feature of most greek key β -barrel proteins. *Prot. Science* 3, 1927-1937.
- Holliger, H. and Winter G. (1993): Engineering bispecific antibodies. *Curr. Opin. Biotech.* 4, 446-449.
- de Kruif, J., Boel, E. and Logtenberg, T. (1995): Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. *J. Mol. Biol.* 248, 97-105.
- Ku, J. and Schultz, P. G. (1995): Alternate protein frameworks for molecular recognition. *Proc. Natl. Acad. Sci. USA* 92, 6552-6556.

- Mayr, E.-M., Jaenicke, R. and Glockshuber, R. (1994): Domain interactions and connecting peptides in lens crystallins. *J. Mol. Biol.* 235, 84-88.
- Mandal, K., Chakrabart, B., Thomson, J. and Siezen, R. J. (1987): Structure and stability of β -crystallins. Denaturation and proteolysis behaviour. *J. Biol. Chem.* 262, 8096-8102.
- McConnell S. and Hoess R. H. (1995): Tendamistat as a scaffold for conformationally constrained phage peptide libraries. *J. Mol. Biol.* 250, 460-470.
- McConnell, S. J., Uveges, A. J., Fowlkes, D. M. and Spinella, D. G (1996): Construction and screening of M13 phage libraries displaying long random peptides. *Mol. Diversity* 1, 165-176.
- Nissim, A., Hoogenboom, H. R., Tomlinson, I. M., Flynn, G., Midgley, C., Lane, D. and Winter, G. (1994): Antibody fragments from a 'single pot' phage display library as immunochemical reagents. *EMBO J.* 13, 692-698.
- Nord K., Gunneriusson, E., Ringdahl, J., Stahl, S., Uhlen, M. and Nygren, P. A. (1997): Binding proteins selected from combinatorial libraries of an β -helical bacterial receptor domain. *Nat. Biotechnol.* 8, 772-777.
- Pack, P. and Plückthun, A. (1992): Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity in *Escherichia coli*. *Biochemistry* 31, 1579-1584.
- Pantoliano, M. W., Bird, R. E., Johnson, S., Asel, E. D., Dodd, S. W., Wood, J. F. and Hardman, K. D. (1991): Conformational stability, folding, and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in *Escherichia coli*. *Biochemistry* 30, 10117-10125.
- Richardson, J. S., Richardson, D. C., Tweedy, N. B., Gernert, K. M., Quinn, T. P., Hecht, M. H., Erickson, B. W., Yan, Y., McClain, R. D., Donlan, M. E. and Surles, M. C. (1992): Looking at proteins: representations, folding, packing and design. *Biophys. J.* 63, 1186-1209.
- Riddle, D. S., Santiago, J. V., Bray-Hall, S. T., Doshi, N., Grantcharova, Q. Y and Baker, D. (1997): Functional rapidly folding proteins from simplified amino acid sequences. *Nature structural biology* 4, 805-809.
- Rudolph, R., Siebendritt, R., Nessler, G., Sharma, A. and Jaenicke, R. (1990): Folding of an all- β protein: independent domain folding in GammaBII-crystallin from calf eye lens. *Proc. Natl. Acad. Sci. USA* 87, 4625-4629.
- Slingsby, C.(1985): Structural variation in lens crystallins. *TIBS* 10, 281-284.
- Smith, G. P (1985): Filamentous Fusion Phage: Novel expression vectors that display cloned antigens on the virion surface. *Science* 228, 1315-1317.
- Stahl, S. and Uhlen, M. (1997): Bacterial surface display: trends and progress. *TIBTECH* 15, 185-192.
- Wistow, G. J. and Piatigorsky, J. (1988): Lens crystallins: the evolution and expression of proteins for a highly specialized tissue. *Ann. Rev. Biochem.* 57, 479-504.

Wistow, G. J., Turnell, B., Summers, L., Slingsby, C. Moss, D., Miller, L., Lindley, P. and Blundell, T. (1983): X-ray analysis of the eye lens protein γ -II-crystallin at 1.9 Å resolution. *J. Mol. Biol.* 170, 175-202.

Young, N. M., MacKenzie, C. R., Narang, S. A., Oomen, R. P. and Baenziger, J. E. (1995): Thermal stabilization of a single-chain Fv antibody fragment by introduction of a disulphide bond. *FEBS Lett.* 377, 135-139.

Ausubel, F.M., Brent, R., Kinston, R.E., Moore, D.D., Seidmann, J.G., Smith, J.A. and Struhl, K. (1994): *Current protocols in molecular biology*. John Wiley & Sons, Inc.

Cramer, A., Dawes, G., Rodriguez, E., Jr., Silver, S. and Stemmer, W.P. (1997): Molecular evolution of an arsenate detoxification pathway by DNA shuffling. *Nat. Biotechnol.* 5, 436-438.

Kuchner, O. and Arnold, F.H. (1997): Directed evolution of enzyme catalysts. *TIBTECH* 15, 523-530.

Pannekoek, H., van Meijer M., Schleef, R.R., Loskutov, d.J. and Barbas, C.F. (1993): Functional display of human plasminogen-activator inhibitor 1 (PAI-1) on phages: Novel perspectives for structure-function analysis by error-prone DNA synthesis. *Gene* 128, 135-140.

Sambrook, J., Maniatis, T. and Fritsch, E.F. (1989): *Molecular Cloning: A laboratory manual*. Cold spring Harbor. Cold Spring Harbour Laboratory Press, New York.

Stemmer, W.P.C. (1994): Rapid evolution of a protein in vitro by DNA shuffling. *Nature* 370, 389-391.

You, L. and Arnold, F.H. (1996): Directed evolution of subtilisin E in *Bacillus subtilis* to enhance total activity in aqueous dimethylformamide. *Protein Eng.* 1, 77-83.

Zhang, J.H., Dawas, G. and Stemmer, W-P. (1997): Directed evolution of a fucosidase from a galactosidase by DNA shuffling and screening. *Proc. Natl. Acad. Sci. U.S.A.* 94, 4504-4509.


1/8

Fig. 1

GCLIE1B: Biotin-
 CGCGCGCTCTCACAAAGATACATGCCATGACTCGCGGCCAGCC
 GCLIE2P: P-
 CCCCATGGCCGGCTGGGCCGCGAGTCATGGCATGTATCTTTGTGAGACGCGCGCG
 GCLI3P: P- GGCCATGGGGNNKATCNNKTTTNNKGAGGACCGGGG
 GCLIB4P: P- GTGGCCCTGGAAGCCCCGGTCCTC
 GCLI5P: P-
 CTTCCAGGGGCCACNNKTACNNKTGCNNKAGCGACTGCCCCAACC
 GCLI6P: P- TGCAGCCCTATTTCAGCCGC
 GCLIB7P: P-
 GATGGAGTTACAGCGGCTGAAATAGGGCTGCAGGTTGGGGCAGTCGC
 GCLI8P: p-
 TGTA ACTCCATC NNKGTGNNKAGCGGCTGCTGGATGCTGTATGAG
 GCLIE9P: P- CGCCCCAACTACCAGGGTCACCAGTACTTCCTGCGGC
 GCLIE10:
 GCCGCAGGAAGTACTGGTGACCCTGGTAGTTGGGGCGCTCATACAGCATC
 GCLIA11B: Biotin- CCATCAGCCCCATCAGCGAACTTTGCCGCAGGAAGTACTGG

P: Phosphate, N: A/C/G/T, K: T/G

Fig. 2



2/8

Fig. 3





Fig. 4

GCFORNOT: 5' GAGTCATTCTGCGGCCGCATAAAAAATCCATCACCCGTCTTAAAGAACC
3'


GCBACKSfiBst: 5'
GCGGCCAGCCGCGCGCTGCTGGATGCTGTATGAGCGCCCCAACTACCAGGGTCACC
AG 3'

3/8

Fig. 5



Polyclonal ELISA after 3rd panning



4/8

Fig. 7

Mu 12A:

GGCCCAGCCGGCCATGGGGAGGATCAAGTTTAAAGAGGACCGGGGCTTCCAGGGCCA
 CTATTACAGTTGCAATAGCGACTGCCCCAACCTGCAGCCCTATTTTCAGCCGCTGTAAC
 CCATCAGGGTGCTGAGCGGCTGCTGGATGCTGTATGAGCGCCCCAACTACCAGGGTCA
 CC

WT:

GGCCCAGCCGGCCATGGGGAAGATCACTTTTTACGAGGACCGGGGCTTCCAGGGCCA
 CTGCTACGAGTGCAAGCAGCGACTGCCCCAACCTGCAGCCCTATTTTCAGCCGCTGTAAC
 TCCATCCGCGTGGACAGCGGCTGCTGGATGCTGTATGAGCGCCCCAACTACCAGGGC
 CACC

Fig. 8

Mu 12A:

AAQPAMGRIKFKE~~DRGFQGHYYSC~~NSDCPNLQPYFSRCNSIRVLSGCWMLYERP~~NYQGH~~
 QYFLRRGDYPDYQQWMGFNDSIRSCRLIPQHTGTFRMRIYERDDFRGQMSEITDDCPSLQ
 DRFHLTEVHSLNVLEGSWVLYEMPSYRGRQYLLRPGEYRRYLDWGAMNAKVGSLRRVMD
 FYAAAGAPVPYPDPLEPRAA

WT:

AAQPAMGKITFYEDRGFQGH~~CYECSS~~DCPNLQPYFSRCNSIRVDSGCWMLYERP~~NYQGH~~
 QYFLRRGDYPDYQQWMGFNDSIRSCRLIPQHTGTFRMRIYERDDFRGQMSEITDDCPSLQ
 DRFHLTEVHSLNVLEGSWVLYEMPSYRGRQYLLRPGEYRRYLDWGAMNAKVGSLRRVMD
 FYAAAGAPVPYPDPLEPRAA

Fig. 9

GC 20bbackWT: 5' GGGAATTCCATATGGGGAAGATCACTTTTTACG 3'
 GC 20bback12A: 5' GGGAATTCCATATGGGGAGGATCAAGTTTAAAG 3'
 GC for 20b: 5' CGCGGATCCGAATAAAAATCCATCACCCG 3'

5/8

Fig. 10

Mu 12A-HIS:

MGR**I**KFKEDRGFQGHY**Y**SCNSDCPNLQPYFSRCNSIRV**L**SGCWMLYERP**N**YQGHQYFLR
 RGDY**P**DYQQWMGFND**S**IRSCRLIPQHTGTFRMRIYERDDFRGQMSEITDDCPSLQDRFHL
 TEVHSLNVLEGS**W**VL**Y**EMPSYRGRQYLLRPGEYRRYLDWGAMNAKVGSLRRVMDFY**SDP**
NSSSVDKLAAALEHHHHHH

WT-HIS:

MGKITFYEDRGFQGH**C**YECSSDCPNLQPYFSRCNSIRVDSGCWMLYERP**N**YQGHQYFLR
 RGDY**P**DYQQWMGFND**S**IRSCRLIPQHTGTFRMRIYERDDFRGQMSEITDDCPSLQDRFHL
 TEVHSLNVLEGS**W**VL**Y**EMPSYRGRQYLLRPGEYRRYLDWGAMNAKVGSLRRVMDFY**SDP**
NSSSVDKLAAALEHHHHHH

Fig. 11







Fig. 12




7/8

Fig. 13A



8/8

Fig. 13B



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)	Attorney Docket Number	1406/37	
	First Named Inventor	Fiedler, Ulrike	
	COMPLETE IF KNOWN		
	Application Number	10 / 030,605	
	Filing Date	January 9, 2002	
	Art Unit		
		Examiner Name	

☐ Declaration Submitted with Initial Filing
 OR
☒ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

As the below named inventor, I hereby declare that:

My residence, mailing address, and citizenship are as stated below next to my name.

I believe I am the original and first inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:

DESIGN OF BETA-PLEATED SHEET PROTEINS WITH SPECIFIC BINDING PROPERTIES

(Title of the Invention)

the specification of which

☐ is attached hereto

OR

☒ was filed on (MM/DD/YYYY) 01/09/2002 as United States Application Number or PCT International

Application Number and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
199 32 688.6 PCT/EP00/06698	Germany WIPO	07/13/1999 07/13/2000	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto

U.S. PATENT AND TRADEMARK OFFICE


PTO/SB/01 (10-01)

Approved for use through 10/31/2002 OMB 0651-0032

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

DECLARATION — Utility or Design Patent Application

Direct all correspondence to: <input checked="" type="checkbox"/>		Customer Number or Bar Code Label		OR <input type="checkbox"/>	Correspondence address below	
25297 PATENT TRADEMARK OFFICE						
Name						
Address						
City			State	ZIP		
Country		Telephone		Fax		
<p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.</p>						
NAME OF SOLE OR FIRST INVENTOR :			<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name 1-00 (first and middle [if any]) Ulrike			Family Name or Surname Fiedler			
Inventor's Signature <i>U. Fiedler</i>			Date 27.02.02			
Residence: City Dresden		State	Country DE	Citizenship DE <i>DEX</i>		
Mailing Address Donndorfstr. 08						
city Dresden		State	ZIP D-01217	Country Germany		
NAME OF SECOND INVENTOR:			<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name 2-00 (first and middle [if any]) Rainer			Family Name or Surname Rudolph			
Inventor's Signature <i>Rainer Rudolph</i>			Date MAR. 5 / 02			
Residence: City Halle		State	Country DE	Citizenship DE <i>DEX</i>		
Dr. Hans-Litten-Strasse 28						
Mailing Address						
city Halle		State	ZIP D-06120	Country Germany		
<input type="checkbox"/> Additional inventors are being named on the 0 supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.						

Sequence Listing

<110> SciI Proteins GmbH
Fiedler, Ulrike
Rudolph, Rainer

<120> DESIGN OF BETA-SHEET PROTEINS WITH SPECIFIC BINDING PROPERTIES

<130> P12389 / 1406-37

<140> US 10/030,605

<141> 2002-01-09

<150> PCT/EP00/06698

<151> 2000-07-13

<160> 25

<170> PatentIn version 3.0

<210> 1

<211> 45

<212> DNA

<213> Artificial

<220>

<223> GCLIE1B primer designed according to mutant bovine gamma-II crystalline DNA sequence. See Figure 1.

<220>

<221> misc_feature

<222> (1)..(45)

<223> GCLIE1B primer designed according to mutant bovine gamma-II crystalline DNA sequence. See Figure 1.

<400> 1
cgcgcgcgctc tcacaaagat acatgccatg actcgcgggcc cagcc 45

<210> 2

<211> 50

<212> DNA

<213> Artificial

<220>

<223> GCLIE10 primer designed according to mutant bovine gamma-II crystalline sequence. See Figure 1.

<220>

<221> misc_feature

<222> (1)..(50)

<223> GCLIE10 primer designed according to mutant bovine gamma-II crystalline DNA sequence. See Figure 1.

<400> 2
gccgcaggaa gtactggtga ccctggtagt tggggcgctc atacagcatc 50

<210> 3

<211> 41

<212> DNA

<213> Artificial

<220>

<223> GLIA11B primer designed according to mutant bovine gamma-II crystalline DNA sequence. See Figure 1.

<220>

```

<221> misc_feature
<222> (1)..(41)
<223> GCLIA11B primer designed according to mutant bovine gamma-II
        crystalline DNA sequence. See Figure 1.
<400> 3
ccatcagccc catcagcgaa ctttgccgca ggaagtactg g
41

<210> 4
<211> 48
<212> DNA
<213> Artificial
<220>
<223> GCFORNOT primer for amplification of bovine gamma-II crystalline DNA
        in plasmid pGII. See Figures 3 and 4.
<220>
<221> misc_feature
<222> (1)..(48)
<223> GCFORNOT primer for amplification of bovine gamma-II crystalline DNA
        in plasmid pGII. See Figures 3 and 4.
<400> 4
gagtcattct gcggccgcat aaaaatccat caccctgttt aaagaacc
48

<210> 5
<211> 59
<212> DNA
<213> Artificial
<220>
<223> GCBACKSfiBst primer for amplification of bovine gamma-II crystalline
        DNA in plasmid pGII. See Figures 3 and 4.
<220>
<221> misc_feature
<222> (1)..(59)
<223> GCBACKSfiBst primer for amplification of bovine gamma-II crystalline
        DNA in plasmid pGII. See Figures 3 and 4.
<400> 5
gcggcccagc cggccgctgc tggatgctgt atgagcgccc caactaccag ggtcaccag
59

<210> 6
<211> 55
<212> DNA
<213> Artificial
<220>
<223> GCBACKSfi primer designed for amplification of bovine gamma-II
        crystalline DNA in plasmid pGII.
<220>
<221> misc_feature
<222> (1)..(55)
<223> GCBACKSfi primer designed for amplification of bovine gamma-II
        crystalline DNA in plasmid pGII.
<400> 6
catgccatga ctgcgggccc agccggccat ggggaagatc actttttacg aggac
55

<210> 7
<211> 26
<212> DNA
<213> Artificial
<220>
<223> pCAR1LAB primer for DNA sequencing.
<220>
<221> misc_feature
<222> (1)..(26)

```

<223> pCAR1LAB primer for DNA sequencing.
 <400> 7
 ccatgattac gccaaagcttt ggagcc 26

<210> 8
 <211> 21
 <212> DNA
 <213> Artificial
 <220>
 <223> GCLISEQ primer for DNA sequencing.
 <220>
 <221> misc_feature
 <222> (1)..(21)
 <223> GCLISEQ primer for DNA sequencing.
 <400> 8
 ctgaaagtgc cgggtgtgttg c 21

<210> 9
 <211> 176
 <212> DNA
 <213> Bos sp.
 <400> 9
 ggcccagccg gccatgggga ggatcaagtt taaagaggac cggggcttcc agggccacta 60
 ttacagttgc aatagcgact gcccacacct gcagccctat ttcagccgct gtaactccat 120
 caggggtgctg agcggctgct ggatgctgta tgagcgcccc aactaccagg gtcacc 176

<210> 10
 <211> 176
 <212> DNA
 <213> Bos sp.
 <400> 10
 ggcccagccg gccatgggga agatcacttt ttacgaggac cggggcttcc agggccactg 60
 ctacgagtgc agcagcgact gcccacacct gcagccctat ttcagccgct gtaactccat 120
 ccgcgtggac agcggctgct ggatgctgta tgagcgcccc aactaccagg gccacc 176

<210> 11
 <211> 55
 <212> DNA
 <213> Artificial
 <220>
 <223> GCLIE2P primer designed according to mutant bovine gamma-II crystalline DNA sequence. See Figure 1.
 <220>
 <221> misc_feature
 <222> (1)..(55)
 <223> GCLIE2P primer designed according to mutant bovine gamma-II crystalline DNA sequence. See Figure 1.
 <400> 11
 ccccatggcc ggctgggccc cgagtcattg catgtatctt tgtgagacgc gcgcg 55

<210> 12
 <211> 36
 <212> DNA
 <213> Artificial
 <220>
 <223> GCLI3P primer designed according to mutant bovine gamma-II crystalline DNA sequence. See Figure 1.

```

<220>
<221> misc_feature
<222> (1)..(36)
<223> GCLI3P primer designed according to mutant bovine gamma-II
crystalline DNA sequence. See Figure 1.

<220>
<221> misc_feature
<222> (1)..(36)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (1)..(36)
<223> k is g or t
<400> 12
ggccatgggg nnkacnkt ttnnkgagga ccgggg 36

<210> 13
<211> 24
<212> DNA
<213> Artificial
<220>
<223> GCLI4P primer designed according to mutant bovine gamma-II
crystalline DNA sequence. See Figure 1.

<220>
<221> misc_feature
<222> (1)..(24)
<223> GCLIB4P primer designed according to mutant bovine gamma-II
crystalline DNA sequence. See Figure 1.
<400> 13
gtggccctgg aagccccggt cctc 24

<210> 14
<211> 44
<212> DNA
<213> Artificial
<220>
<223> GCLI5P primer designed according to mutant bovine gamma-II
crystalline DNA sequence. See Figure 1.

<220>
<221> misc_feature
<222> (1)..(44)
<223> GCLI5P primer designed according to mutant bovine gamma-II
crystalline DNA sequence. See Figure 1.

<220>
<221> misc_feature
<222> (1)..(44)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (1)..(44)
<223> k is g or t
<400> 14
cttccagggc cacnktacn nktgcnnkag cgactgcccc aacc 44

<210> 15
<211> 20
<212> DNA
<213> Artificial
<220>
<223> GCLI6P primer designed according to mutant bovine gamma-II
crystalline DNA sequence. See Figure 1.

```

<220>
 <221> misc_feature
 <222> (1)..(20)
 <223> GCLI6P primer designed according to mutant bovine gamma-II
 crystalline DNA sequence. See Figure 1.
 <400> 15
 tgcagcccta tttcagccgc 20

 <210> 16
 <211> 47
 <212> DNA
 <213> Artificial
 <220>
 <223> GCLI7P primer designed according to mutant bovine gamma-II
 crystalline DNA sequence. See Figure 1.
 <220>
 <221> misc_feature
 <222> (1)..(47)
 <223> GCLIB7P primer designed according to mutant bovine gamma-II
 crystalline DNA sequence. See Figure 1.
 <400> 16
 gatggagtta cagcggctga aatagggctg caggttgggg cagtcgc 47

 <210> 17
 <211> 45
 <212> DNA
 <213> Artificial
 <220>
 <223> GCLI8P primer designed according to mutant bovine gamma-II
 crystalline DNA sequence. See Figure 1.
 <220>
 <221> misc_feature
 <222> (1)..(45)
 <223> GCLI8P primer designed according to mutant bovine gamma-II
 crystalline DNA sequence. See Figure 1.
 <220>
 <221> misc_feature
 <222> (1)..(45)
 <223> n is a, c, g, or t
 <220>
 <221> misc_feature
 <222> (1)..(45)
 <223> k is g or t
 <400> 17
 tgtaactcca tcnnkgtggn kagcggctgc tggatgctgt atgag 45

 <210> 18
 <211> 37
 <212> DNA
 <213> Artificial
 <220>
 <223> GCLIE9P primer designed according to mutant bovine gamma-II
 crystalline DNA sequence. See Figure 1.
 <220>
 <221> misc_feature
 <222> (1)..(37)
 <223> GCLIE9P primer designed according to mutant bovine gamma-II
 crystalline DNA sequence. See Figure 1.
 <400> 18
 cgccccaact accagggtca ccagtacttc ctgcggc 37

<210> 19
 <211> 198
 <212> PRT
 <213> Bos sp.
 <400> 19

Ala	Ala	Gln	Pro	Ala	Met	Gly	Arg	Ile	Lys	Phe	Lys	Glu	Asp	Arg	Gly
1				5					10					15	
Phe	Gln	Gly	His	Tyr	Tyr	Ser	Cys	Asn	Ser	Asp	Cys	Pro	Asn	Leu	Gln
	20							25					30		
Pro	Tyr	Phe	Ser	Arg	Cys	Asn	Ser	Ile	Arg	Val	Leu	Ser	Gly	Cys	Trp
	35						40					45			
Met	Leu	Tyr	Glu	Arg	Pro	Asn	Tyr	Gln	Gly	His	Gln	Tyr	Phe	Leu	Arg
	50					55					60				
Arg	Gly	Asp	Tyr	Pro	Asp	Tyr	Gln	Gln	Trp	Met	Gly	Phe	Asn	Asp	Ser
65					70					75				80	
Ile	Arg	Ser	Cys	Arg	Leu	Ile	Pro	Gln	His	Thr	Gly	Thr	Phe	Arg	Met
			85					90						95	
Arg	Ile	Tyr	Glu	Arg	Asp	Asp	Phe	Arg	Gly	Gln	Met	Ser	Glu	Ile	Thr
			100					105					110		
Asp	Asp	Cys	Pro	Ser	Leu	Gln	Asp	Arg	Phe	His	Leu	Thr	Glu	Val	His
		115					120					125			
Ser	Leu	Asn	Val	Leu	Glu	Gly	Ser	Trp	Val	Leu	Tyr	Glu	Met	Pro	Ser
	130					135					140				
Tyr	Arg	Gly	Arg	Gln	Tyr	Leu	Leu	Arg	Pro	Gly	Glu	Tyr	Arg	Arg	Tyr
145					150					155					160
Leu	Asp	Trp	Gly	Ala	Met	Asn	Ala	Lys	Val	Gly	Ser	Leu	Arg	Arg	Val
				165					170					175	
Met	Asp	Phe	Tyr	Ala	Ala	Ala	Gly	Ala	Pro	Val	Pro	Tyr	Pro	Asp	Pro
			180					185					190		
Leu	Glu	Pro	Arg	Ala	Ala										
				195											

<210> 20
 <211> 198
 <212> PRT
 <213> Bos sp.
 <400> 20

Ala	Ala	Gln	Pro	Ala	Met	Gly	Lys	Ile	Thr	Phe	Tyr	Glu	Asp	Arg	Gly
1				5					10					15	
Phe	Gln	Gly	His	Cys	Tyr	Glu	Cys	Ser	Ser	Asp	Cys	Pro	Asn	Leu	Gln
	20							25					30		
Pro	Tyr	Phe	Ser	Arg	Cys	Asn	Ser	Ile	Arg	Val	Asp	Ser	Gly	Cys	Trp
	35						40					45			

Met Leu Tyr Glu Arg Pro Asn Tyr Gln Gly His Gln Tyr Phe Leu Arg
50 55 60

Arg Gly Asp Tyr Pro Asp Tyr Gln Gln Trp Met Gly Phe Asn Asp Ser
65 70 75 80

Ile Arg Ser Cys Arg Leu Ile Pro Gln His Thr Gly Thr Phe Arg Met
85 90 95

Arg Ile Tyr Glu Arg Asp Asp Phe Arg Gly Gln Met Ser Glu Ile Thr
100 105 110

Asp Asp Cys Pro Ser Leu Gln Asp Arg Phe His Leu Thr Glu Val His
115 120 125

Ser Leu Asn Val Leu Glu Gly Ser Trp Val Leu Tyr Glu Met Pro Ser
130 135 140

Tyr Arg Gly Arg Gln Tyr Leu Leu Arg Pro Gly Glu Tyr Arg Arg Tyr
145 150 155 160

Leu Asp Trp Gly Ala Met Asn Ala Lys Val Gly Ser Leu Arg Arg Val
165 170 175

Met Asp Phe Tyr Ala Ala Ala Gly Ala Pro Val Pro Tyr Pro Asp Pro
180 185 190

Leu Glu Pro Arg Ala Ala
195

<210> 21
<211> 197
<212> PRT
<213> Bos sp.
<400> 21

Met Gly Arg Ile Lys Phe Lys Glu Asp Arg Gly Phe Gln Gly His Tyr
1 5 10 15

Tyr Ser Cys Asn Ser Asp Cys Pro Asn Leu Gln Pro Tyr Phe Ser Arg
20 25 30

Cys Asn Ser Ile Arg Val Leu Ser Gly Cys Trp Met Leu Tyr Glu Arg
35 40 45

Pro Asn Tyr Gln Gly His Gln Tyr Phe Leu Arg Arg Gly Asp Tyr Pro
50 55 60

Asp Tyr Gln Gln Trp Met Gly Phe Asn Asp Ser Ile Arg Ser Cys Arg
65 70 75 80

Leu Ile Pro Gln His Thr Gly Thr Phe Arg Met Arg Ile Tyr Glu Arg
85 90 95

Asp Asp Phe Arg Gly Gln Met Ser Glu Ile Thr Asp Asp Cys Pro Ser
100 105 110

Leu Gln Asp Arg Phe His Leu Thr Glu Val His Ser Leu Asn Val Leu
115 120 125

Glu Gly Ser Trp Val Leu Tyr Glu Met Pro Ser Tyr Arg Gly Arg Gln
130 135 140

Tyr Leu Leu Arg Pro Gly Glu Tyr Arg Arg Tyr Leu Asp Trp Gly Ala
145 150 155 160

Met Asn Ala Lys Val Gly Ser Leu Arg Arg Val Met Asp Phe Tyr Ser
165 170 175

Asp Pro Asn Ser Ser Ser Val Asp Lys Leu Ala Ala Ala Leu Glu His
180 185 190

His His His His
195

<210> 22
<211> 197
<212> PRT
<213> Bos sp.
<400> 22

Met Gly Lys Ile Thr Phe Tyr Glu Asp Arg Gly Phe Gln Gly His Cys
1 5 10 15

Tyr Glu Cys Ser Ser Asp Cys Pro Asn Leu Gln Pro Tyr Phe Ser Arg
20 25 30

Cys Asn Ser Ile Arg Val Asp Ser Gly Cys Trp Met Leu Tyr Glu Arg
35 40 45

Pro Asn Tyr Gln Gly His Gln Tyr Phe Leu Arg Arg Gly Asp Tyr Pro
50 55 60

Asp Tyr Gln Gln Trp Met Gly Phe Asn Asp Ser Ile Arg Ser Cys Arg
65 70 75 80

Leu Ile Pro Gln His Thr Gly Thr Phe Arg Met Arg Ile Tyr Glu Arg
85 90 95

Asp Asp Phe Arg Gly Gln Met Ser Glu Ile Thr Asp Asp Cys Pro Ser
100 105 110

Leu Gln Asp Arg Phe His Leu Thr Glu Val His Ser Leu Asn Val Leu
115 120 125

Glu Gly Ser Trp Val Leu Tyr Glu Met Pro Ser Tyr Arg Gly Arg Gln
130 135 140

Tyr Leu Leu Arg Pro Gly Glu Tyr Arg Arg Tyr Leu Asp Trp Gly Ala
145 150 155 160

Met Asn Ala Lys Val Gly Ser Leu Arg Arg Val Met Asp Phe Tyr Ser
165 170 175

Asp Pro Asn Ser Ser Ser Val Asp Lys Leu Ala Ala Ala Leu Glu His
180 185 190

His His His His
195


```

<210> 23
<211> 33
<212> DNA
<213> Artificial
<220>
<223> GC20bbackWT primer for cloning bovine gamma-II crystalline DNA into
vector pET-205. See Figure 9.
<220>
<221> misc_feature
<222> (1)..(33)
<223> GC20bbackWT primer for cloning bovine gamma-II crystalline DNA into
vector pET-205. See Figure 9.
<400> 23
gggaattcca tatggggaag atcacttttt acg                                     33

<210> 24
<211> 33
<212> DNA
<213> Artificial
<220>
<223> GC20bback12A primer for cloning Mul2A into vector pET-205. See
Figure 9.
<220>
<221> misc_feature
<222> (1)..(33)
<223> GC20bback12A primer for cloning Mul2A into vector pET-205. See
Figure 9.
<400> 24
gggaattcca tatggggagg atcaagttta aag                                     33

<210> 25
<211> 29
<212> DNA
<213> Artificial
<220>
<223> GCfor20 primer for cloning Mul2A and bovine gamma-II crystalline DNA
into vector pET-205. See Figure 9.
<220>
<221> misc_feature
<222> (1)..(29)
<223> GCfor20 primer for cloning Mul2A and bovine gamma-II crystalline DNA
into vector pET-205. See Figure 9.
<400> 25
cgcggatccg aataaaaatc catcacccg                                     29

```

SEQUENCE LISTING

<110> Fiedler, Dr. Ulrike
Rudolph, Prof. Dr. Rainer

<120> Design of beta-sheet proteins with specific
binding properties

<130> P12389

<140>

<141>

<150> DE 199 32 688.6

<151> 1999-07-13

<160> 22

<170> PatentIn Ver. 2.1

<210> 1

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence: oligonucleotide

<400> 1

cgcgcgcgtc tcacaaagat acatgccatg actcgcggcc cagcc

45

<210> 2

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence: oligonucleotide

<400> 2

gccgcaggaa gtactggtga ccctggtagt tggggcgctc atacagcatc

50

<210> 3

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence: oligonucleotide

<400> 3

ccatcagccc catcagcgaa ctttgccgca ggaagtactg g

41

<210> 4

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

Sequence: oligonucleotide

<400> 4
gagtcattct gcggccgcat aaaaatccat caccgtctt aaagaacc 48

<210> 5
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence: oligonucleotide

<400> 5
gcggcccagc cgccgctgc tggatgctgt atgagcgccc caactaccag ggtcaccag 59

<210> 6
<211> 55
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence: oligonucleotide

<400> 6
catgccatga ctgcgggccc agccggccat ggggaagatc actttttacg aggac 55

<210> 7
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence: oligonucleotide

<400> 7
ccatgattac gccaaagcttt ggagcc 26

<210> 8
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence: oligonucleotide

<400> 8
ctgaaagtgc cggtgtgttg c 21

<210> 9
<211> 176
<212> DNA
<213> Bos sp.

<400> 9
ggcccagccg gccatgggga ggatcaagtt taaagaggac cggggcttcc agggccacta 60
ttacagttgc aatagcgact gcccacacct gcagccctat ttcagccgct gtaactccat 120
caggggtgctg agcggctgct ggatgctgta tgagcgcccc aactaccagg gtcacc 176

<210> 10
 <211> 176
 <212> DNA
 <213> Bos sp.

<400> 10
 ggcccagccg gccatgggga agatcacttt ttacgaggac cggggcttcc agggccactg 60
 ctacgagtgc agcagcgact gcccacacct gcagccctat ttcagccgct gtaactccat 120
 ccgctgtggac agcggctgct ggatgctgta tgagcgcccc aactaccagg gccacc 176

<210> 11
 <211> 54
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial
 Sequence: oligonucleotide

<400> 11
 ccccatggcc ggctgggccc cgagtcattg catgtatctt tgtgagacgc gcgcg 54

<210> 12
 <211> 36
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial
 Sequence: oligonucleotide

<400> 12
 ggccatgggg nnkatcnkt ttnnkgagga ccgggg 36

<210> 13
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial
 Sequence: oligonucleotide

<400> 13
 gtggccctgg aagccccggt cctc 24

<210> 14
 <211> 44
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial
 Sequence: oligonucleotide

<400> 14
 cttccagggc cacnnktacn nktgcnnkag cgactgcccc aacc 44

<210> 15
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence: oligonucleotide

<400> 15

tgcagcccta tttcagccgc

20

<210> 16

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence: oligonucleotide

<400> 16

gatggagtta cagcggctga aatagggctg caggttgggg cagtcgc

47

<210> 17

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence: oligonucleotide

<400> 17

tgtaactcca tcnnkgtggn kagcggctgc tggatgctgt atgag

45

<210> 18

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence: oligonucleotide

<400> 18

cgccccact accaggtca ccagtacttc ctgcggc

37

<210> 19

<211> 198

<212> PRT

<213> Bos sp.

<400> 19

Ala Ala Gln Pro Ala Met Gly Arg Ile Lys Phe Lys Glu Asp Arg Gly
1 5 10 15

Phe Gln Gly His Tyr Tyr Ser Cys Asn Ser Asp Cys Pro Asn Leu Gln
20 25 30

Pro Tyr Phe Ser Arg Cys Asn Ser Ile Arg Val Leu Ser Gly Cys Trp
35 40 45

Met Leu Tyr Glu Arg Pro Asn Tyr Gln Gly His Gln Tyr Phe Leu Arg
50 55 60

Arg Gly Asp Tyr Pro Asp Tyr Gln Gln Trp Met Gly Phe Asn Asp Ser
65 70 75 80

Ile Arg Ser Cys Arg Leu Ile Pro Gln His Thr Gly Thr Phe Arg Met
85 90 95
Arg Ile Tyr Glu Arg Asp Asp Phe Arg Gly Gln Met Ser Glu Ile Thr
100 105 110
Asp Asp Cys Pro Ser Leu Gln Asp Arg Phe His Leu Thr Glu Val His
115 120 125
Ser Leu Asn Val Leu Glu Gly Ser Trp Val Leu Tyr Glu Met Pro Ser
130 135 140
Tyr Arg Gly Arg Gln Tyr Leu Leu Arg Pro Gly Glu Tyr Arg Arg Tyr
145 150 155 160
Leu Asp Trp Gly Ala Met Asn Ala Lys Val Gly Ser Leu Arg Arg Val
165 170 175
Met Asp Phe Tyr Ala Ala Ala Gly Ala Pro Val Pro Tyr Pro Asp Pro
180 185 190
Leu Glu Pro Arg Ala Ala
195

<210> 20
<211> 198
<212> PRT
<213> Bos sp.

<400> 20
Ala Ala Gln Pro Ala Met Gly Lys Ile Thr Phe Tyr Glu Asp Arg Gly,
1 5 10 15
Phe Gln Gly His Cys Tyr Glu Cys Ser Ser Asp Cys Pro Asn Leu Gln
20 25 30
Pro Tyr Phe Ser Arg Cys Asn Ser Ile Arg Val Asp Ser Gly Cys Trp
35 40 45
Met Leu Tyr Glu Arg Pro Asn Tyr Gln Gly His Gln Tyr Phe Leu Arg
50 55 60
Arg Gly Asp Tyr Pro Asp Tyr Gln Gln Trp Met Gly Phe Asn Asp Ser
65 70 75 80
Ile Arg Ser Cys Arg Leu Ile Pro Gln His Thr Gly Thr Phe Arg Met
85 90 95
Arg Ile Tyr Glu Arg Asp Asp Phe Arg Gly Gln Met Ser Glu Ile Thr
100 105 110
Asp Asp Cys Pro Ser Leu Gln Asp Arg Phe His Leu Thr Glu Val His
115 120 125
Ser Leu Asn Val Leu Glu Gly Ser Trp Val Leu Tyr Glu Met Pro Ser
130 135 140
Tyr Arg Gly Arg Gln Tyr Leu Leu Arg Pro Gly Glu Tyr Arg Arg Tyr
145 150 155 160
Leu Asp Trp Gly Ala Met Asn Ala Lys Val Gly Ser Leu Arg Arg Val

165

170

175

Met Asp Phe Tyr Ala Ala Ala Gly Ala Pro Val Pro Tyr Pro Asp Pro
180 185 190

Leu Glu Pro Arg Ala Ala
195

<210> 21
<211> 197
<212> PRT
<213> Bos sp.

<400> 21
Met Gly Arg Ile Lys Phe Lys Glu Asp Arg Gly Phe Gln Gly His Tyr
1 5 10 15
Tyr Ser Cys Asn Ser Asp Cys Pro Asn Leu Gln Pro Tyr Phe Ser Arg
20 25 30
Cys Asn Ser Ile Arg Val Leu Ser Gly Cys Trp Met Leu Tyr Glu Arg
35 40 45
Pro Asn Tyr Gln Gly His Gln Tyr Phe Leu Arg Arg Gly Asp Tyr Pro
50 55 60
Asp Tyr Gln Gln Trp Met Gly Phe Asn Asp Ser Ile Arg Ser Cys Arg
65 70 75 80
Leu Ile Pro Gln His Thr Gly Thr Phe Arg Met Arg Ile Tyr Glu Arg
85 90 95
Asp Asp Phe Arg Gly Gln Met Ser Glu Ile Thr Asp Asp Cys Pro Ser
100 105 110
Leu Gln Asp Arg Phe His Leu Thr Glu Val His Ser Leu Asn Val Leu
115 120 125
Glu Gly Ser Trp Val Leu Tyr Glu Met Pro Ser Tyr Arg Gly Arg Gln
130 135 140
Tyr Leu Leu Arg Pro Gly Glu Tyr Arg Arg Tyr Leu Asp Trp Gly Ala
145 150 155 160
Met Asn Ala Lys Val Gly Ser Leu Arg Arg Val Met Asp Phe Tyr Ser
165 170 175
Asp Pro Asn Ser Ser Ser Val Asp Lys Leu Ala Ala Ala Leu Glu His
180 185 190
His His His His His
195

<210> 22
<211> 197
<212> PRT
<213> Bos sp.

<400> 22
Met Gly Lys Ile Thr Phe Tyr Glu Asp Arg Gly Phe Gln Gly His Cys

● ● ● ●

[illegible]

10030605.003102

10/030605

531 Rec'd PCT/

09 JAN 2002

P12389.sequence engl.txt
SEQUENCE LISTING

<110> Fiedler, Dr. Ulrike
Rudolph, Prof. Dr. Rainer

<120> Design of beta-sheet proteins with specific
binding properties

<130> P12389

<140>

<141>

<150> DE 199 32 688.6

<151> 1999-07-13

<160> 22

<170> PatentIn Ver. 2.1

<210> 1

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence: oligonucleotide

<400> 1

cgcgcgcgtc tcacaaagat acatgccatg actcgcggcc cagcc

45

<210> 2

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence: oligonucleotide

<400> 2

gccgcaggaa gtactggtga ccctggtagt tggggcgctc atacagcatc

50

<210> 3

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence: oligonucleotide

<400> 3

ccatcagccc catcagcgaa ctttgccgca ggaagtactg g

41

<210> 4

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial

Sequence: oligonucleotide

<400> 4
gaqtcatctt gcggccgcat aaaaatccat caccgcgtctt aaagaacc 48

<210>	5
<211>	59
<212>	DNA
<213>	Artificial Sequence

<220>
<223> Description of Artificial
Sequence: oligonucleotide

<400> 5
gcggcccagc cggccgctgc tggatgctgt atgagcgccc caactaccag ggtcaccag 59

```
<210> 6
<211> 55
<212> DNA
<213> Artificial sequence
```

<220>
<223> Description of Artificial
Sequence: oligonucleotide

<400> 6
catgccatga ctcgcggccc agccggccat ggggaagatc actttttacg aggac 55

<210>	7
<211>	26
<212>	DNA
<213>	Artificial sequence

<220>
<223> Description of Artificial
Sequence: oligonucleotide

<400> 7
ccatgattac gccaaagcttt ggagcc 26

```
<210> 8
<211> 21
<212> DNA
<213> Artificial sequence
```

<220>
<223> Description of Artificial
Sequence: oligonucleotide

<400> 8
ctgaaagtgc cgggtgtgttg c 21

<210>	9
<211>	176
<212>	DNA
<213>	Bos sp.

```
<400> 9
ggcccagccg gccatgggga ggatcaagtt taaagaggac cggggcttcc agggccacta 60
ttacagttgc aatagcgact gccccaacct gcagccctat ttacagcgct gtaactccat 120
caggggtgctg aqcggctgct ggatgctgta tgagcgcccc aactaccagg gtcacc      176
```

P12389.sequence engl.txt

```

<210> 10
<211> 176
<212> DNA
<213> Bos sp.

<400> 10
ggcccagccg gccatgggga agatcacttt ttacgaggac cggggcttcc agggccactg 60
ctacgagtgc agcagcgact gccccaacct gcagccctat ttcagccgct gtaactccat 120
ccgcgtggac agcggctgct ggatgctgta tgagcgcccc aactaccagg gccacc 176

<210> 11
<211> 54
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence: oligonucleotide

<400> 11
ccccatggcc ggctgggccc cgagtcattg catgtatctt tgtgagacgc gcgcg 54

<210> 12
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence: oligonucleotide

<400> 12
ggccatgggg nnkacnkt ttnkgagga ccgggg 36

<210> 13
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence: oligonucleotide

<400> 13
gtggccctgg aagccccggt cctc 24

<210> 14
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence: oligonucleotide

<400> 14
cttcagggc cacnktacn nktgcnnkag cgactgcccc aacc 44

<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

```

P12389.sequence engl.txt

<220>

<223> Description of Artificial
Sequence: oligonucleotide

<400> 15

tgcagcccta tttcagccgc

20

<210> 16

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence: oligonucleotide

<400> 16

gatggagtta cagcggctga aatagggctg caggttgggg cagtcgc

47

<210> 17

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence: oligonucleotide

<400> 17

tgtaactcca tcnnkgtgnn kagcggctgc tggatgctgt atgag

45

<210> 18

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence: oligonucleotide

<400> 18

cgccccaact accaggggtca ccagtacttc ctgcggc

37

<210> 19

<211> 198

<212> PRT

<213> Bos sp.

<400> 19

Ala Ala Gln Pro Ala Met Gly Arg Ile Lys Phe Lys Glu Asp Arg Gly
1 5 10 15

Phe Gln Gly His Tyr Tyr Ser Cys Asn Ser Asp Cys Pro Asn Leu Gln
20 25 30

Pro Tyr Phe Ser Arg Cys Asn Ser Ile Arg Val Leu Ser Gly Cys Trp
35 40 45

Met Leu Tyr Glu Arg Pro Asn Tyr Gln Gly His Gln Tyr Phe Leu Arg
50 55 60

Arg Gly Asp Tyr Pro Asp Tyr Gln Gln Trp Met Gly Phe Asn Asp Ser
65 70 75 80

P12389.sequence engl.txt

165

170

175

Met Asp Phe Tyr Ala Ala Ala Gly Ala Pro Val Pro Tyr Pro Asp Pro
180 185 190

Leu Glu Pro Arg Ala Ala
195

<210> 21
<211> 197
<212> PRT
<213> Bos sp.

<400> 21
Met Gly Arg Ile Lys Phe Lys Glu Asp Arg Gly Phe Gln Gly His Tyr
1 5 10 15

Tyr Ser Cys Asn Ser Asp Cys Pro Asn Leu Gln Pro Tyr Phe Ser Arg
20 25 30

Cys Asn Ser Ile Arg Val Leu Ser Gly Cys Trp Met Leu Tyr Glu Arg
35 40 45

Pro Asn Tyr Gln Gly His Gln Tyr Phe Leu Arg Arg Gly Asp Tyr Pro
50 55 60

Asp₆₅ Tyr Gln Gln Trp Met₇₀ Gly Phe Asn Asp Ser₇₅ Ile Arg Ser Cys Arg₈₀

Leu Ile Pro Gln His Thr Gly Thr Phe Arg Met Arg Ile Tyr Glu Arg
85 90 95

Asp Asp Phe Arg Gly Gln Met Ser Glu Ile Thr Asp Asp Cys Pro Ser
100 105 110

Leu Gln Asp Arg Phe His Leu Thr Glu Val His Ser Leu Asn Val Leu
115 120 125

Glu Gly Ser Trp Val Leu Tyr Glu Met Pro Ser Tyr Arg Gly Arg Gln
130 135 140

Tyr Leu Leu Arg Pro Gly Glu Tyr Arg Arg Tyr Leu Asp Trp Gly Ala
145 150 155 160

Met Asn Ala Lys Val Gly Ser Leu Arg Arg Val Met Asp Phe Tyr Ser
165 170 175

Asp Pro Asn Ser Ser Ser Val Asp Lys Leu Ala Ala Ala Leu Glu His
180 185 190

His His His His His
195

<210> 22
<211> 197
<212> PRT
<213> Bos sp.

<400> 22
Met Gly Lys Ile Thr Phe Tyr Glu Asp Arg Gly Phe Gln Gly His Cys
Page 6

P12389.sequence engl.txt

1	5	10	15
Tyr	Glu	Cys	Ser
	20	Ser	Asp
Cys	Asn	Ser	Ile
	35	Arg	Val
Pro	Asn	Tyr	Gln
	50	Gly	His
Asp	Tyr	Gln	Gln
	65	Trp	Met
Leu	Ile	Pro	Gln
	80	His	Thr
Asp	Asp	Phe	Arg
	100	Gly	Gln
Leu	Gln	Asp	Arg
	115	Phe	His
Glu	Gly	Ser	Trp
	130	Val	Leu
Tyr	Leu	Leu	Arg
	145	Pro	Gly
Met	Asn	Ala	Lys
	160	Val	Gly
Asp	Pro	Asn	Ser
	175	Ser	Ser
His	His	His	His
	190	His	His

P12389.sequence eng1.txt

11/11/2019 11:11:11 AM

P12389.sequence engl.txt